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Abstract 
The combination of HIV and cryptococcal meningitis (CM) is a major cause of morbidity and 
mortality in sub-Saharan Africa. The phylogenetic relatedness of HIV-1 subtype C (HIV-1C) 
variants in peripheral blood and the central nervous system (CNS) compartments of individuals 
with CM is unknown. Additionally, the major and alternative coreceptor usage of HIV-1C in 
those compartments are not clear and these have implications for the pathogenesis of the virus, 
and the use of coreceptor blocking therapies.  
For genotypic studies, 16 antiretroviral therapy naïve individuals with CM were randomly 
selected. We conducted single-genome, or bulk PCR amplification and sequencing of full-length 
HIV-1 env genes from plasma and/or cerebrospinal fluid (CSF) of the participants. Additionally, 
we estimated the prevalence of CXCR4-using variants in our cohort using coreceptor usage 
prediction algorithms (CPAs). Next, we evaluated the usage of CCR3, CCR5 and CXCR4 
expressed on NP2/U87-CD4 cells by HIV-1C Envs derived from the plasma and/or CSF of 14 of 
the 16 participants.  
In all 11 of the 16 participants with HIV-1C env sequences available from matched plasma and 
CSF samples, we observed genetic intermixing of viral variants between compartments using a 
neighbor-joining phylogenetic tree. In two participants, CM089 and CM112, with multiple 
sequences collected from both compartments using single-genome amplification and sequencing 
exclusively, compartmentalized variants were not observed in CM089 and CM112 using the 
Slatkin-Maddison test (p-value 0.19 and 0.35, respectively), and this result was confirmed by the 
Hudson nearest-neighbor test (p-value 0.34 and 0.54, respectively). Using a combination of 
publicly available coreceptor usage prediction algorithms (Geno2pheno, PhenoSeq and 
WebPSSM subtype C sinsi), ~44% of participants were predicted to possess CXCR4-using 
variants.  
HIV-1C in plasma and/CSF samples of 14 of the 16 participants was then evaluated for the ability 
to use CCR3, CCR5 and CXCR4. We showed that HIV-1C is capable of using CCR5, CXCR4 or 
xviii 
 
CCR3 alone, or in combination with the other receptors. Overall, our results have improved the 
understanding of HIV-1C pathogenesis in the peripheral blood and CNS compartments of 
individuals with end-stage infection and CM, and provides clinically relevant information for 
therapies including coreceptor antagonists in this setting.
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Chapter 1: Introduction 
1.1. HIV: The etiological agent of the AIDS pandemic 
Acquired immune deficiency syndrome (AIDS) observed in a series of cases among homosexual 
men in the year 1981 marked the emergence of a new epidemic (1-3). The human 
immunodeficiency virus type 1 (HIV-1) which was implicated as the cause of the AIDS epidemic 
had been characterized initially by three different research groups by the end of the year 1984. 
Each group, however, had named the virus in their own way. Researchers at the Pasteur Institute 
(Paris, France) named the virus “lymphadenopathy-associated virus” (LAV), whereas researchers 
at the National Cancer Institute (Bethesda, USA) named it “human T-cell lymphotropic virus type 
III” (HTLV-III), and a group at the University of California (California, USA) named it “AIDS-
associated retrovirus” (ARV) (4-7). 
There are two types of human immunodeficiency virus (HIV), 1 (HIV-1) and 2 (HIV-2), which 
belong to a family of primate lentiviruses that includes the simian immunodeficiency virus (SIV) 
(8). Notably, HIV-1 arose from a form of SIV which infected chimpanzees and was able to 
establish itself in a human host through cross-species transmission. SIV, unlike HIV-1 or HIV-2, 
infects non-human primates, whereas HIV-1 and HIV-2 are adapted to humans as hosts (9-11). 
HIV-1 and HIV-2 are not equally pathogenic (12), nor are they equally distributed globally. HIV-
1 is composed of groups M (major), N (non-M, non-O), O (outlier) and P, though it is group M 
which is responsible for the global epidemic, contributing approximately 60 million infections 
and 25 million deaths to date (13). It is not known for sure how the first individual(s) were infected 
with HIV, but it is suspected that they were exposed to ape blood products containing the virus in 
West Africa (Kinshasa, formerly Leopoldville), and that the virus entered their body cutaneously 
or through exposed membranes (14, 15).  
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1.2. HIV-1 exhibits high genetic diversity 
Within HIV-1 group M there are subtypes A-K, circulating recombinant forms (CRFs) and unique 
recombinant forms (URFs) which are unevenly distributed across the globe (Figure 1.1) (16). 
HIV-1 subtype C (HIV-1C) is responsible for 48% of infections globally, followed by subtype A 
(HIV-1A; 12%), subtype B (HIV-1B; 11%), CRF02_AG (8%), CRF01_AE (5%), subtype G (5%) 
and D (HIV-1D; 2%). Other CRFs and URFs each account for 4% of infections, while the 
remaining subtypes account for less than 1% of all infections (17, 18). Sequence differences 
within subtypes may be between 15-20%, but may be up to 30% between subtypes (19). When 
HIV-1 is transmitted from a donor to a recipient, a severe genetic bottleneck selects for only a 
single or very limited number of variants to establish infection. Transmitted viruses generally 
have low genetic diversity, with one viral variant being sufficient to establish infection in 
approximately 80% of infected individuals (20, 21).  
The high genetic diversity which arises eventually within and between individuals is due to the 
high replication rate of the virus, the error-prone nature of its reverse transcriptase (RT) enzyme 
which has little or no proof-reading ability (22), and the intense immune pressure exerted by the 
host (23-26). In effect, a “swarm” of diverse viruses (better known as the quasispecies) forms 
within an infected individual, with viral variants in the population displaying varied genetic and 
phenotypic properties (27, 28). 
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Figure 1.1: The distribution of HIV-1 subtypes across the globe. 
In the main figure, pie-charts show the share of infections each HIV-1 subtype is responsible for 
in a specific geographical region. The size of each pie-chart reflects the total number of infections 
in a region relative to other pie-charts. The legend on the left-side of the main figure shows the 
subtypes corresponding to the colors shown in each pie-chart. In the inserts of the main figure, 
the distribution of HIV-1 subtypes in Central Africa and the world are shown. Reproduced from 
Hemelaar (2012) (13). 
 
1.3. The genomic composition of HIV-1 
The genome of HIV-1 is approximately 10 kilobases (kb) long (29). Different genes are 
responsible for coding for different structures of the virus (Figure 1.2). The gag gene codes for 
the p17, p24, and the p7/p9 proteins. The pol gene codes for the protease, RT and integrase 
enzymes. The env gene codes for the precursor gp160 protein molecule which is cleaved by a 
cellular protease to produce non-covalently associated gp120 and gp41 heterodimers. Regulatory 
and accessory proteins are encoded by the tat, rev, vif, vpu, vpr, rev, as well as nef gene. The ends 
of the HIV genome have the untranslated long terminal repeat (LTR) sequences.  
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Figure 1.2. The genome structure of HIV-1.  
The organization of the genes coding for the different gene products of HIV-1 is shown. The open 
reading frame for each genomic region is shown as a rectangle. Reproduced with modifications 
from Cassis-Ghavami et al (2009) (30). 
 
1.4. The arrangement of major HIV-1 proteins 
The mature HIV-1 particle is between 110 and 128 nanometers (nm) in diameter (31). The core 
of the virus is cone-shaped (32) and composed of a major capsid protein (p24) and nucleocapsid 
protein (p7/p9) which encase two single-stranded RNA genome copies, protease, RT and 
integrase enzymes. The core itself is surrounded by the matrix protein (p17), while the envelope 
glycoproteins (Envs) (composed of gp41 and gp120 heterodimers) coat the outside of the virus, 
as they are embedded in a lipid bilayer derived from the host (Figure 1.3).  
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Figure 1.3. The arrangement of HIV-1 proteins and RNA in a virion. 
Reproduced from Stevens and Papathanasopoulos (2009) (33). 
 
1.5. The functions of the major HIV-1 proteins 
HIV-1 Env is responsible for attachment of the virus to the host cell, and facilitates the fusion of 
the viral membrane with the host membrane (34, 35). The RT enzyme, a key component of the 
retrovirus, converts the RNA genome into DNA to form what is known as the provirus (22). The 
integrase enzyme facilitates integration of the reverse-transcribed viral genome into the host 
genome (36, 37). The Gag polyprotein (composed of the p7/p9, p17 and p24 proteins) allows for 
the assembly of mature virus particles (38). HIV protease processes the Gag and Gag-Pol 
polyprotein into individual proteins (39). The Tat protein regulates virus transcription initiation 
(40), and the Rev protein facilitates the export of HIV RNA, spliced and unspliced, from the 
nucleus to the cytoplasm (41). Nef downregulates cell-surface receptors such as the CD4 and 
major histocompatibility complex class I molecules  (42, 43), Vpr enhances virus replication (44, 
45), Vif regulates the infectivity of virions (46-48), and Vpu improves the release of virions from 
the host cell (49-51).  
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1.5.1 The structure of HIV-1 Envs 
The Env protein of HIV-1 is initially synthesized as a 160 kilodalton (kD) precursor protein 
(Figure 1.4) which is subsequently cleaved to yield a gp120 portion (120 kD in size) that is non-
covalently associated to a gp41 portion (41 kD in size) (52). Three gp120-gp41 heterodimers 
associate non-covalently with each other on the surface of the virus, forming a trimer or spike 
(Figure 1.5). There are an estimated 14 spikes on average on each virus particle (53). The gp120 
portion is typically heavily glycosylated and possesses five constant (C1-C5) and five variable 
regions (V1-V5). It is divided into three distinct sub-domains; the inner, outer and bridging sheet. 
Notably, this protein has a site which binds to CD4 and another site which binds to a chemokine 
coreceptor, though the amino acids responsible for binding at either site are discontinuous (54). 
The gp41 portion is composed of an extracellular domain, a membrane-spanning domain, and a 
cytoplasmic tail. The extracellular domain is composed of a fusion peptide, an N-terminal heptad 
repeat (NHR), a loop region, C-terminal heptad repeat (CHR), and a membrane-proximal external 
region (55).  
 
1.5.2 The main function of HIV-1 Envs 
Virus attachment to host cells is initiated with the engagement of cell-surface CD4 by HIV-1 
gp120 of Env (34), followed by a number of conformational changes within gp120 which permit 
the engagement of a chemokine receptor (54, 56). The major coreceptors usually engaged by 
HIV-1 are CCR5 and CXCR4; both are seven-pass G-protein coupled chemokine receptors which 
act as cofactors for entry for most variants (57-59). Conformational changes in gp41 then arise 
which allow its fusion peptide to penetrate the host cell membrane while a pre-hairpin fusion 
intermediate of the NHR trimer forms. Three CHR molecules then pack tightly together in an 
anti-parallel fashion into the hydrophobic grooves of the NHR trimer. This causes the viral and 
host membranes to come closer to each other and fuse (Figure 1.6) (55). 
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Figure 1.4. The HIV-1 gp160 precursor protein.  
The residues shown as black spheres indicate the location of disulphide bonds. SP, ETD, TMD 
and CTD refer to the gp120 signal peptide, gp41 ectodomain, transmembrane domain and 
cytoplasmic tail domain, respectively. Reproduced from van Anken et al (2008) (60). 
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Figure 1.5: The HIV-1 envelope trimer 
The three glycosylated gp120-gp41 heterodimers which form one HIV-1 envelope trimer were 
crystalized by Lee et al (2015; PDB ID: 5ACO) (61). The yellow, purple and brown ribbon 
structures represent gp120 portions. The pink, cyan and blue ribbon structures represent gp41 
portions. The red spheres represent the glycan structures. The image was generated using The 
PyMOL Molecular Graphics System, evaluation version 1 Schrödinger, LLC. 
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Figure 1.6: The attachment and fusion steps of HIV-1 entry 
The attachment of HIV-1 to the host cell requires the initial engagement of the gp120 portion of 
the envelope protein (Env) with cell-surface CD4. Conformational changes within gp120 arise, 
including the exposure of the V3 loop by the V1/V2 loops of Env. The coreceptor binding site of 
Env which includes the V3 loop then binds a chemokine coreceptor, usually CCR5 or CXCR4. 
Viruses which use CCR5 preferentially typically have a low net charge of the V3 loop, and dock 
onto the N-terminus and extracellular loop 1 (ECL-1) of CCR5. CXCR4-using viruses typically 
have high net charge of the V3 and dock onto the N-terminus and ECL-2 of CXCR4. After the 
engagement of the coreceptor, more conformational changes in gp120 expose the gp41 portion of 
Env. Gp41 facilitates the fusion of the virus and host membrane, affording the virus an 
opportunity to translocate its core into the host cell. Reproduced from Aiamkitsumrit et al (2014) 
(62). 
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1.5.2.1 The HIV-1 Env V3  
The third variable region (V3), amino acids 296-331 according to HXB2 numbering, of HIV-1 
Env is typically 35 (range: 31-39) amino acids in length. It plays an important role during the 
attachment step of the HIV-1 life-cycle, as it forms part of the coreceptor binding site which 
determines which coreceptor, usually CCR5 or CXCR4, will be used for entry (Figure 1.6 and 
Figure 1.7) (reviewed by Hartley et al., 2005) (63). It is composed of three structural regions; a 
base, flexible stem, and a β-hairpin tip (Figure 1.8) (64).  
 
Figure 1.7: The HIV-1 gp120 core with V3 region bound to CD4. 
The crystal structure of soluble two-domain CD4 (red) in complex with the JR-FL gp120 core 
(green) is shown (PDB ID: 2B4C). The intact V3 region (white) which is part of the gp120 protein, 
and interacts with a chemokine coreceptor, typically CCR5 or CXCR4, is also shown. Reproduced 
from Huang et al (2005) (64). 
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Figure 1.8: The structure and protein sequence of the HIV-1 Env V3. 
(A) The crystal structure of the HIV-1 JR-FL Env V3 region (color code: grey, carbon atoms; 
blue, nitrogen atoms; red, oxygen atoms; and orange, disulfide bond) (PDB ID: 2B4C). The three 
sub-regions of the V3 (the base, stem and β-hairpin tip) are shown. (B) The Env V3 protein 
sequences of JR-FL and HXB2 are shown along with those of consensus subtype A, B and C 
viruses. Uppercase letters in the consensus sequences show conserved residues, while lowercase 
letter show variable residues. The conserved arginine-proline (yellow) and crown (green) motifs 
are indicated. The blue, magenta, and red line below the sequences correspond to the base, stem 
and β-hairpin tip sub-regions of the V3. Reproduced from Huang et al (2005) (64).  
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The Env V3 region was initially shown to determine the cytopathicity, cellular tropism and 
infectivity of HIV-1 (65-67). After the discovery of coreceptors which act as cofactors for HIV-
1 entry, mutational analyses of the V3 showed that it was the major determinant of CCR5 and/or 
CXCR4 usage (68). Within the V3, specific residues were observed only in viruses which bound 
to CCR5. A serine or glycine (uncharged residues) at position 11, and glutamic acid or aspartic 
acid (negatively charged residues) at position 25 was found in CCR5-using isolates, but an 
arginine (positively charged residue) or glutamine (uncharged) at one or both positions conferred 
the ability to use other coreceptors (69). Other modifications of the V3 which were shown to alter 
coreceptor usage for HIV-1B and HIV-1C isolates were the overall net charge and the number of 
potential N-linked glycosylation sites (PNGS), where an increased overall net charge and reduced 
number of PNGS, individually, conferred usage of CXCR4. These results suggested that the 
requirements for coreceptor switching for HIV-1B and HIV-1C were the same (70). Later studies 
showed that there were other determinants of CXCR4 usage. The sequence variability of R5 and 
CXCR4-using viruses was different, with R5 viruses having lower variability than CXCR4-using 
viruses (71). The crown motif sequence of the V3, GPGQ, is characteristic of R5 viruses (72), but 
CXCR4-using viruses frequently have alterations of the motif and/or a two-amino acid insertion 
beside the motif (73-77). 
Although the V3 is the major determinant of coreceptor usage, other regions of Env have been 
shown to contribute to usage of coreceptors. Modifications in the V1-V2 region were shown to 
contribute to a switch of major coreceptor (68, 78-80). The observation that certain dualtropic 
Envs share an identical V3 sequence with R5 Envs (81), and that a single amino acid mutation in 
the gp41 protein may confer tropism for CXCR4 (82), confirms that the V3 is the major but not 
the sole determinant of coreceptor switching.  
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1.6. The life-cycle of HIV-1 
The HIV-1 Env protein mediates the attachment of the virus to the host cell, and fusion of the 
virus and host cell membranes. Thereafter, the virus is able to transfer its core, including the 
nucleocapsid, into the cytosol of the host cell. The RNA genome strands of HIV-1 encased by the 
nucleocapsid are then exposed and associate with RT, integrase, Vpr, and an array of host proteins 
to form a pre-integration complex which migrates to the nucleus of the cell (83). Reverse 
transcription is performed by the RT enzyme, and the remaining RNA template is degraded by 
the RNAse H portion of RT. Because RT has poor proof-reading ability, mutations are 
incorporated into the proviral DNA genome of HIV-1, thereby increasing the genetic diversity of 
the virus population over time (22, 84).  
For replication, HIV-1 must insert a copy of its genome into the host genome. After reverse 
transcription, the integrase enzyme supported by other proteins facilitates the integration of the 
proviral (double-stranded) DNA genome into the host genome (85-87). In some cases auto-
integration occurs where the linear proviral DNA forms 2-LTR circles, or 1-LTR circle after the 
recombination of the LTR ends (86). 
The transcription of balanced amounts of spliced and unspliced proviral DNA is required for 
efficient viral replication. The integrated proviral genome of HIV-1 may occupy resting cells 
(hence the persistence of latent HIV-1 reservoirs despite antiretroviral therapy) or active cells. In 
both cases, the Tat protein of HIV-1 along with other host cellular factors initiate transcription 
from the transacting response element (TAR) in the LTR for the generation of mRNA molecules 
(88). From one proviral genome more than 30 mRNA molecules may be generated through 
alternative splicing; unspliced products include the approximately 10 kilobase transcript, or 
transcripts of varying sizes after splicing (89).  
The translation of HIV-1 mRNA transcripts leads to the synthesis of Gag, Gag-Pol, Vpr and Vif 
proteins along with two viral RNA genome molecules, which are all assembled at the plasma 
membrane of the host cell to make a virion (90). Host proteins such as tumor suppressor gene 101 
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are diverted from their normal roles to work in combination with viral proteins to assemble virions 
(91, 92). The budding of virions occurs preferentially in micro-domains of the plasma membrane 
where cholesterol is richly deposited (93), and is assisted by the Vpu protein of the virus. So 
important is Vpu that viruses with a defective version of the protein are unable to be released from 
the host cell (94). Notably, HIV-1 may be released from an infected cell at cell-to-cell membrane 
sites where intercellular adhesion molecules such as ICAM-1 are concentrated. The incorporation 
of host adhesion molecules in the virion, and the co-localization of budding virions and host 
adhesion molecules during syncytium formation are important for viral spread (95). Once the 
virion is released from the cell it is able to infect new cellular targets in a cell-free manner, or 
spread from the infected cell to an uninfected cell; the latter occurring via a virological synapse 
which spreads HIV more efficiently (96). 
 
1.6.1 Inhibiting steps of the HIV-1 life-cycle 
Different steps of the life-cycle of HIV-1 may be targeted using combination antiretroviral therapy 
(cART) (Figure 1.9). More than 25 compounds have been approved by the Food and Drug 
Administration (FDA) for use as anti-HIV compounds, as reviewed by De Clercq (2009) (97). 
The different anti-HIV compounds fall into one of five classes based on the targets they block or 
the step of the HIV life-cycle they stop from proceeding. Nucleoside analogue reverse 
transcriptase inhibitors (NRTIs) and nucleotide reverse transcriptase inhibitors (NtRTIs) form one 
class, while non-nucleoside reverse transcriptase inhibitors (NNRTIs) form a second class, though 
both classes describe reagents which target the reverse transcription step by inhibiting the function 
of the RT enzyme. Protease inhibitors are a third class of reagents which target HIV protease and 
prevent it from performing its proteolytic processing function. The strand-transfer reaction 
catalyzed by the integrase enzyme is blocked from proceeding by integrase inhibitors. Attachment 
and fusion inhibitors form their own class of drugs as they prevent entry of HIV into the cell: the 
fusion of viral and host membranes is inhibited by Enfuvirtide (also known as T-20), a 36 amino 
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acid peptide fusion inhibitor which binds to the gp41 protein (98). The use of CCR5 by HIV Env 
is prevented by maraviroc, a CCR5 antagonist which blocks entry (99).  
Despite the ability of monotherapy or cART to reduce the viral load, boost CD4 cell count and 
slow disease progression (100, 101), the efficacy of the treatment is undermined by its high 
toxicity and the ability of HIV-1 to mount resistance (102, 103). It was initially recommended in 
the year 2006 that a NNRTI (or a protease inhibitor boosted with ritonavir) be used in combination 
with two NRTIs, unless the patient profile required otherwise, only after the CD4  cell count of an 
individual dropped to 350 or 200 cells/µL (104). By the year 2012, new recommendations were 
provided, advising that two NRTIs (Tenofovir/Emtricitabine or Abacavir/Lamivudine), a NNRTI 
(Efavirenz), a ritonavir-boosted protease inhibitor (Atazanavir or Duranavir) or an integrase 
inhibitor (Raltegravir) be used by patients, unless their clinical profile required otherwise. 
Additionally, it was recommended that all patients use cART regardless of their CD4 cell count 
and viral load (105). The benefits of early initiation of cART were confirmed by the Strategic 
Timing of Antiretroviral Treatment (START) Study Group. The group showed that it was 
immediate treatment of HIV-1, when individuals had a CD4 count higher than 500 cell/µL and 
not when the CD4 count had declined to 350 cells/µL, that provided better clinical outcomes for 
infected individuals (106).  
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Figure 1.9: The life-cycle of HIV-1 and the inhibition of steps thereof 
HIV-1 enters a host cell after its envelope protein (Env) binds to CD4 and a chemokine coreceptor, 
usually CCR5 or CXCR4. Conformational changes in Env facilitate the fusion of the viral and 
host cell membranes which lead to the transfer of the viral core into the host cell. In the cytosol, 
HIV-1 RNA is reverse transcribed and the pre-integration complex is formed before it is targeted 
to the nucleus. Inside the nucleus, the double-stranded DNA provirus is integrated into the host 
genome. New viral RNA genomes, core proteins and enzymes are then generated from the 
integrated provirus. New virions are made and released after a process of budding and maturation. 
Nucleoside analogue reverse transcriptase inhibitors (NRTIs) as well as non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) block reverse transcription from proceeding. Integrase strand 
transfer inhibitors (InSTIs) and allosteric integrase inhibitors (ALLINIs) block the process of 
integration facilitated by the viral integrase enzyme. Protease inhibitors prevent the protease 
enzyme from maturing the assembled virion. Coreceptor antagonists and fusion inhibitors block 
the entry of viruses into the host cells.  Reproduced from Laskey and Siliciano (2014) (107). 
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1.7. HIV-1 disease progression 
Although there is person to person variation, the CD4+ T-cell count and viral load dynamics 
during the course of untreated infection are consistent (Figure 1.10). In a review by Coffin and 
Swanstrom (2013) (108), the authors describe the clinical response of individuals from the time 
they are infected with HIV-1 until they die of AIDS. In the first two weeks after infection (the 
eclipse phase), viremia is not readily detectable in blood though the virus is replicating unchecked 
and spreading from the initial site of infection to other tissues and organs which also support viral 
replication. At this stage the host immune response is ignorant of the presence of the virus and no 
symptoms are presented by the infected individual. Between the second and fourth week of 
infection (primary/acute infection), the HIV viral load spikes to as high as 107 RNA 
copies/milliliter (mL) in the blood while the CD4+ T-cell count declines transiently. Concurrently, 
the host immune response recruits CD8+ T-cells to target viral antigens expressed on infected 
cells and antibodies are produced which attempt to neutralize or control virus replication. Towards 
the end of this phase of infection the viral load declines due to the action of the CD8+ T-cells and 
possibly antibodies and innate immune responses. Symptoms presented by individuals in this 
stage of infection include fever and enlarged lymph nodes, similar to influenza infections. Clinical 
latency follows the acute infection stage and may last approximately one to 20 years. Here, the 
viral load is relatively stable, and the CD4+ T-cell count recovers from its lowest point but does 
not returned to pre-infection levels. Typically, infected individuals are asymptomatic and not 
aware that they harbor HIV. Nevertheless, CD4+ T-cells are persistently killed due to the infection 
and steadily decline in number (108). When the CD4+ T-cell count number drops to approximately 
200 cells/microlitre (µL), and the immune system is unable to control the infection, opportunistic 
infections start to appear. The HIV viral load spikes to exceedingly high levels once more, 
reminiscent of the acute stage of infection. In this end-stage of disease individuals are diagnosed 
as having AIDS and die if left untreated. The prognosis for untreated AIDS patients is poor as the 
mortality rate is above 95% (108). Common opportunistic infections experienced by individuals 
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with AIDS are Mycobacterium tuberculosis or avium complex, cryptococcal meningitis, 
Pneumocystis jirovecii pneumonia (formerly known as Pneumocystis carinii), diarrhea-associated 
diseases, candidiasis, cytomegalovirus retinitis, histoplasmosis, progressive multifocal 
leukoencephalopathy, Kaposi’s sarcoma and non-Hodgkin lymphoma (109). 
 
Figure 1.10. The HIV disease progression of the average individual not on antiretroviral 
therapy. 
Early in acute infection, the HIV RNA load increases drastically while the CD4+ T-cell count 
drops slightly. Cytotoxic T-lymphocytes aid in the partial control of virus replication and reduce 
it to a set point, allowing the partial recovery of the CD4+ T-cell count and the onset of clinical 
latency. The set point of the HIV RNA load is correlated with the rate of disease progression. 
After clinical latency and the deterioration of the immune system, the HIV RNA load rises 
drastically once more while the CD4+ T-cell count of the infected individual drops to below 200 
cells/µL, allowing opportunistic infection to arise. Reproduced from Coffin and Swanstrom 
(2013) (108). 
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1.7.1 Cryptococcal meningitis in persons living with HIV-1 
Cryptococcal meningitis (CM) is an opportunistic infection commonly experienced by 
immunosuppressed individuals with end-stage HIV infection (110). The causative agents of CM, 
Cryptococcus neoformans (C. neoformans) and gattii (C. gattii), are the two Cryptococcus species 
which infect humans (111), though C. neoformans is responsible for the majority of central 
nervous system (CNS) cryptococcosis events in individuals living with HIV/AIDS. In patients 
presenting with CM, inflammation of the meninges due to C. neoformans infection, may present 
with varying forms and degrees of neurological deterioration, manifesting as neck stiffness, 
headaches, confusion, altered levels of consciousness, visual impairments and encephalitis (112, 
113). Without rapid treatment including amphotericin B, flucytocine or fluconazole, 100% of 
individuals with CM will die (114). The distribution of CM cases globally is not even, with sub-
Saharan African accounting for approximately 720,000 of the 957,900 (~75.2%) total cases 
annually. HIV-related CM disease is associated with poor clinical outcome with as high as 
624,725 deaths recorded annually; 504,000 of those deaths were in sub-Saharan Africa (115).  
Although individuals with advanced HIV infection and CM may harbor CXCR4-using HIV-1 
(116), thus precluding them from using cART regimes including maraviroc, an accurate 
estimation of the prevalence of CXCR4-using HIV-1 in individuals with CM is unavailable. If 
the prevalence is high, patients may need to be screened for the presence of CXCR4-using HIV-
1 before initiating regimens including maraviroc.  
 
1.7.1.1 The life-cycle of Cryptococcus neoformans 
Reviews by Idnurm et al (2005) and Kwon-Chung et al (2014) have discussed the life-cycle of 
C. neoformans (117, 118). C. neoformans is a heterothallic organism: two compatible partners of 
opposite mating types (MATα and MATa) are required for mating to occur. Before strains of 
opposing mating types come into contact with each other, haploid C. neoformans cells bud 
asexually to propagate themselves. Once the MATα and MATa mating types of C. neoformans 
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come into contact with each other, they each release unique pheromones. Thereafter, the growth 
of the MATa strain becomes isotropic (uniform in all directions) while the MATα strain forms 
conjugation tubules. Fusion of the two strains by virtue of conjugation tubules produces dikaryotic 
hyphae with fused connections (119). During the mating process, mitochondria of the MATα 
strain are eliminated and only those of the MATa strain are preserved and inherited by progeny 
produced after mating (118, 120). The nuclei of the two mating strains fuse to making a diploid 
nucleus that undergoes one round of meiotic division which results in the generation of four 
haploid nuclei. After that, the products of the meiotic division subsequently undergo mitotic 
divisions and budding to produce chains of basidiospores (sexual spores) consisting of MATα and 
MATa type spores (118).  
MATα strains may reproduce unisexually and produce basidiospores which are morphologically 
identically to basidiospores produced by opposing mating types (monokaryotic fruiting). 
However, this form of reproduction generates unfused clamp connections (117, 118). 
Furthermore, the mitochondria are inherited from MATa strains only (121). It is thought that this 
form of reproduction may provide a survival advantage under harsh or changing conditions such 
as nutrient limitations. In favorable conditions, mating and monokaryotic fruiting may be 
stimulated due to darkness, nitrogen starvation, desiccation, and mating pheromones (117).   
 
1.7.1.2 The pathogenesis of Cryptococcus 
Infection occurs when the spores of Cryptococcus or desiccated yeast cells which circulate in the 
air are inhaled by an individual and then deposit themselves in the alveoli of the lung. In the 
presence of a strong cell-mediated immune response, Cryptococcus may be cleared. However, if 
it is not cleared, it may be controlled by the immune system through the development of 
granuloma (117). Immunosuppressed individuals are unable to control or clear Cryptococcus 
which subsequently migrates through the blood, reaches the blood-brain barrier (BBB) and passes 
through it to enter the CNS. The main mechanism of crossing the BBB may be by transcytosis 
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(122), and phagosomal extrusion (also known as the “Trojan-horse mechanism”) (123). A third 
mechanism of entry into the CNS may be through the tight junctions which hold together the brain 
microvascular endothelial cells that make up the BBB, but clear evidence of this has not been 
shown (122). In the CNS, Cryptococcus reaches the meninges and causes inflammation thereof 
as it replicates rapidly, leading to the development of meningoencephalitis or CM.  
 
1.8. The main target cells of HIV-1 
HIV-1 is able to infect different types of cells usually expressing CD4 on their surface. The cells 
targeted by HIV-1 include dendritic cells, activated and inactivated CD4+ T-cell lymphocytes, 
macrophages, and cells of the CNS such as astrocytes and microglia. In vivo, the preferred target 
of HIV-1 is the activated or HIV-specific memory T-cell (124-128). The cause of T-cell death is 
mostly due to necrosis, lysis, pyroptosis or cytopathic effects (129-132). Additionally, the death 
of cells via bystander effects, where uninfected cells in the vicinity of infected cells die has also 
been observed (133). CD4+ T-cells live for a short period of time, constituting short-lived 
reservoirs, whereas macrophages and dendritic cells are long-lived reservoirs which can sustain 
HIV for weeks or months (127, 134). HIV replicates extremely well, and completes its life-cycle 
in approximately 2.5 days, generating over 10 billion virus particles daily (135).  
 
1.9. The biological phenotype of HIV-1 
HIV-1 isolates were initially characterized as non-syncytium-inducing (NSI) or syncytium-
inducing (SI) for cytopathology characterizations, and slow/low or rapid/high when characterized 
according to its replication. Furthermore, NSI and SI isolates were associated with the slow/low 
and the rapid/high phenotypes, respectively (136-138). After CCR5 and CXCR4 were identified 
to act as cofactors for entry of HIV-1 into host cells (57, 58, 139), NSI and SI isolates were 
identified to use these coreceptors differently. NSI isolates predominantly used CCR5, whereas 
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SI isolates used CXCR4 alone or in combination with CCR5. Additionally, the slow/low 
replication phenotypes was associated with the usage of CCR5, whereas the rapid/high phenotype 
was observed in isolates that used CCR5 and other coreceptors including CXCR4 (140). The 
observation that all SI isolates infect lymphocytes from donors who do not express functional 
CCR5, and that NSI isolates are dependent on CCR5 for entry, created certain assumptions about 
the biological phenotype of HIV-1. The assumptions were that NSI isolates were macrophage-
tropic and had the slow/low rate of replication, while SI isolates are T-cell tropic and have the 
rapid/high replication phenotype (69). Because of the inconsistencies observed when 
characterizing the biological phenotype of HIV-1 according to replication rate, syncytium 
inducing ability, and tropism for macrophages or CD4+ T cell, a new way of characterizing the 
phenotype of HIV-1 was devised based on the usage of major coreceptors exclusively. Viruses 
which used CCR5 exclusively were termed R5, those that used CXCR4 exclusively were termed 
X4, and viruses which used CCR5 and CXCR4 (dualtropic) were termed R5X4 (141).  
 
Besides CCR5 and CXCR4, some variants of HIV-1 are capable of using alternative coreceptors 
for entry. Using cells lines induced to express selected coreceptors on their surface, HIV-1 has 
been shown to enter cells using the following alternative coreceptors: APJ, CCR1, CCR2b, CCR3, 
CCR8, CX3CR1, CXCR6, CMKLR1, D6, FPRL1, GPR15, RDC-1 and STRL33 (142-150). 
Usage of certain alternative coreceptors is not consistent between subtypes as HIV-1B variants 
were shown to have robust usage of CCR3, whereas HIV-1A and HIV-1C variants preferred using 
FPRL1 over CCR3, and HIV-1D was unable to use CCR3 or FPRL1 (146). Normally, variants 
use alternative coreceptors along with CCR5 and/or CXCR4, but one report showed that a rare 
transmitted/founder HIV-1B variant was able to enter cell lines expressing GPR15, APJ and 
FPRL1 while it did not use CCR5 or CXCR4 (151). A subset of HIV-1B isolates are able to use 
CCR5 as well as CCR3 to enter microglia, major target cells of HIV-1 in the CNS (152-154), 
while some variants depend on CCR5 primarily for entry (155). Blocking of CCR3 and CCR5 
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with antibodies, however, does not prevent infection of microglia by some viruses as other 
receptors may be used by HIV-1 (156). Although alternative coreceptors may be used to enter 
primary cells such as PBMCs (144, 157, 158), it is unclear what the importance of alternative 
coreceptor usage is for disease progression as individuals in end-stage disease may have variants 
which do not use alternative coreceptors (72). It is suggested, however, that the additional usage 
of alternative coreceptors may contribute to the pathogenicity of HIV-1 (159).  
In one study, HIV-1C from the central nervous system (CNS) has been shown to use CXCR6 
frequently unlike other subtypes, suggesting that they may be a subtype-specific preference of 
alternative coreceptor usage in the CNS (160). CCR3 is an alternative coreceptor previously 
shown to support infection of microglia (153), a major target of HIV-1 in the CNS, though it is 
not known whether HIV-1C from the CNS is capable of using this coreceptor for entry. If HIV-
1C in the CNS is capable of using CCR3, this may impact the pathogenesis of the virus in the 
CNS compartment and potentially undermine the efficacy of maraviroc used to treat CCR5-using 
viruses in that compartment. Further investigations about the alternative coreceptor usage of HIV-
1C in the CNS are required to understand the pathogenesis of the virus in that compartment and 
to optimize therapies which include entry inhibitors.  
 
1.9.1 Major coreceptor usage and disease progression 
Individuals who inherit a homozygous defect of the CCR5 gene, which results in a 32 base pair 
deletion of the gene, are not susceptible to infection by viruses despite repeated exposure, 
providing evidence that R5 variants establish HIV infection (161, 162). The CD4+ T-cells of these 
individuals are, however, infected in vitro by viral variants which use CXCR4 for entry (163). 
Individuals who are heterozygous for the defective gene have slower disease progress than those 
with intact copies of the CCR5 gene (164).  
The switch of major coreceptors by HIV-1 from exclusive usage of CCR5 to the additional or 
exclusive usage of CXCR4 is often accompanied by the usage of alternative coreceptors (165, 
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166). Approximately 50% of individuals with chronic stage HIV-1B harbor viruses which switch 
to using CXCR4, and this is associated with progression to AIDS (167, 168). However, a 
coreceptor switch is not compulsory for disease progression or the development of AIDS, as 
individuals with R5 variants exclusively may develop AIDS without CXCR4-using variants. In 
fact, some cohorts did not have a single individual infected with a HIV-1C CXCR4-using, as 
CCR5-using variants dominated irrespective of the stage of disease progression (72, 169). Other 
studies, however, debunked the assumption that HIV-1C is incapable of using CXCR4, as they 
noted rare usage of CXCR4 by HIV-1C (170, 171). In contrast, a few studies indicate that usage 
of CXCR4 by HIV-1C is not uncommon and may be observed in up to 30% of antiretroviral 
therapy naïve individuals, albeit those with advanced or end-stage HIV disease progression of 
AIDS (116, 172, 173). It was suggested that HIV-1C may be evolving the ability to use CXCR4 
more frequently over time (173), but it is incompletely clear what the causes or requirements of 
enhanced CXCR4 usage by HIV-1C are.  
 
1.9.2 Cellular tropism 
The vast majority of HIV-1 isolates infect CD4+ T-cells at all stages of disease (124, 174). 
However, some strains of HIV-1 have the ability to infect macrophages and to sustain replication 
in this cell type longer than in CD4+ T-cells (175, 176). Viruses adapted to replicate in cells of the 
lymphoid lineage (T-cell tropic; T-tropic) often are unable to infect macrophages productively. 
On the other hand, viruses which productively infect macrophages (macrophage-tropic; M-tropic) 
have better host-cell range, as they are able to additionally infect CD4+ T-cells efficiently (177).  
A population bottleneck is associated with transmitted HIV-1 variants, where a single R5 
transmitted/founder (T/F) virus typically establishes infection (21). The R5 T/F viruses infect 
CD4+ T-cell efficiently, and have modest capacity to infect monocyte-derived macrophages 
(MDMs) which are a surrogate of primary macrophages (178). Unlike prototypic M-tropic strains 
of HIV-1 which efficiently infect MDMs, such as HIV-1Ba-L, T/F viruses have significantly lower 
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infectivity in MDMs, suggesting that macrophage tropism (M-tropism) is not a requirement for 
transmission (179).  
 
The development and determinants of M-tropism are different from individual to individual, as 
reviewed by Arrildt et al (2012) (180), however, what is consistent is that determinants of M-
tropism are within Env, where single amino acids or regions have been associated with M-tropism 
(181-186). M-tropic viruses are linked with the ability to enter cells expressing low levels of CD4 
on their surface (187-190). Given that M-tropic viruses were frequently observed in individuals 
with advanced/end stages of infection, it was suggested that HIV-1 may become M-tropic when 
the host becomes immunosuppressed and target cells expressing CCR5 are depleted (191). 
Furthermore, the absence of M-tropic viruses in individuals with acute and chronic infection (147) 
supported information suggesting that M-tropism arises in end stage disease, and may be enriched 
in anatomical compartments where the cells express low levels of CD4 on their surface. Although 
M-tropic viruses were frequently isolated from the brain of individuals experiencing severe forms 
of HAND (181, 192, 193), these viruses have also been identified circulating in the blood (194).  
 
The majority of HIV-1 variants circulating in the blood, lymph nodes and semen are unable to 
infect macrophages (190). In contrast, macrophages and microglia resident in the CNS are 
susceptible to infection by HIV-1, and this may ultimately lead to the development of HIV-
associated neurological disorders (HAND) (195). CCR5 is the main coreceptor used for entry in 
macrophages and microglia (153, 154, 156, 196), and supports HIV-1 infection in more than one 
part of the brain (192, 197). However, a subset of X4 viruses have the capacity to infect 
macrophages and microglia (198, 199). Besides the major coreceptors, alternative coreceptors 
appear important for entry into microglia also. CCR3, which is expressed on microglia alongside 
CCR5 and CXCR4, and may be used by some strains of HIV-1 to infect this cell type (152-154). 
Taken together, cellular tropism is not restricted by coreceptor usage. Instead, M-tropism of HIV-
1 is predictive of neurotropism (192).  
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The ability of HIV-1 to infect MDMs has been used as a standard to determine whether it was M-
tropic or T-tropic (reviewed by Arrildt et al., 2012 and Josephs et al., 2015) (180, 200). It was 
recently established that M-tropic viruses infect MDMs on average ~28-fold more efficiently than 
T-tropic viruses (201). A limitation of this method is that MDMs vary in their ability to support 
infection, and with M-tropic viruses having various efficiencies of infection, M-tropism is 
therefore not well defined. Thus, due to variability between donor samples and sampling time-
points, or the preparation of the assay, some T-tropic viruses would be qualified as M-tropic, 
while M-tropic viruses would be classified as T-tropic (reviewed by Arrildt et al., 2012 and Joseph 
et al., 2015) (180, 200). A new, accurate method for characterizing M-tropism involves the 
evaluation of HIV-1 entry in Affinofile 293 cells (202). The levels of CD4 and CCR5 on the 
surface of Affinofile 293 cells may be induced independently and simultaneously, such that they 
reflect the phenotype of cells from the myeloid (expressing low densities of CD4) or lymphoid 
(expressing high densities of CD4) lineage (194, 201-203).  With this method, M-tropic virus 
have been identified to efficiently enter Affinofile 293 cells expressing as low as ~1,200-1,400 
CD4 receptors per cell, while T-tropic viruses from the same individual are at least 15% less 
efficient at infecting the cells using the same number of receptors (203).  
 
1.10. HIV in the central nervous system 
1.10.1 Trafficking of HIV-1 into the CNS 
The blood-brain barrier (BBB) is a biological, physical and immunological separator of the 
peripheral blood and CNS compartments (204). Essentially, it is composed of brain microvascular 
endothelial cells (BMECs) held together by tight junction proteins, which determine the 
permeability of the BBB also. Below the BMECs lie the astrocytes, perivascular macrophages, 
microglia and neurons which regulate the function of the BMECs. There are three main ways 
which HIV-1 uses to gain entry into the CNS from peripheral blood (Figure 1.11) (205). The first 
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mechanism is by diapedesis of infected CD14+/CD16+ monocytes or macrophages which are 
major reservoirs of HIV-1 and contribute to the establishment of virus in the CNS. This mode of 
viral trafficking is also known as the “Trojan-horse mechanism”. One study showed that HIV-1 
infected CD14+/CD16+ monocytes circulating in peripheral blood may be recruited into the CNS 
to perform immune surveillance, thus trafficking HIV-1 across the BBB and into the CNS (206).  
Like the CD14+/CD16+ monocytes, infected macrophages from the periphery may also enter the 
CNS and introduce glia to HIV infection. Replication of HIV-1 in the CNS leads to the added 
recruitment of activated CD14+/CD16+ monocytes from the periphery via cytokine-chemokine 
networks (207). HIV-1 infected cells and bystander cells in the CNS secrete pro-inflammatory 
cytokines, chemokines and other compounds which may be neurotoxic, leading to neuronal 
dysfunction (208). A second way of HIV-1 trafficking into the CNS may involve the tight 
junctions which hold together the BMECs that compose the BBB and keep the transport of cells 
and substances regulated. The loss of tight junction integrity increases the permeability of the 
BBB allowing monocytes to migrate into the CNS (209, 210). HIV-1 gp120 and Tat proteins, 
individually, have the ability to affect the integrity of tight junctions by regulating their expression 
and distribution (211). A third mechanism of viral trafficking is by transcytosis, where BMECs 
are permissively infected by HIV-1 in a non-cytolytic way. Infected BMECs may allow leakage 
of cytokines and chemokines from the CNS to peripheral blood, thus affecting the regulated 
transport of substances across the BBB and also increasing the inflow of infected leukocytes into 
the CNS from the periphery. Naturally, CNS cells intimately associated with the infected BMEC 
are then exposed and infected by HIV-1 as well (212). 
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Figure 1.11: The trafficking of HIV-1 from peripheral blood to the central nervous system 
(CNS) 
The blood-brain barrier (BBB) is a physical barrier composed of brain microvascular endothelial 
cells (BMECs) which regulates the movement of cells and substances between the peripheral 
blood and CNS compartments. The predominant target cells of HIV-1 in peripheral blood are the 
CD4+ T-cells. In the CNS, microglia, perivascular macrophages and astrocytes are targeted by 
HIV-1. There are three main ways HIV-1 may enter the CNS from the periphery: The virus may 
enter the CNS through disrupted tight junctions which hold together the BMECs (A). HIV-1 in 
the periphery may enter BMECs via transcytosis (a non-cytolytic processes) and then be 
introduced to target cells in the CNS (B). HIV-1 infected mononuclear phagocytes (CD14+/CD16+ 
monocytes or macrophages) in the periphery may be introduced into the CNS via diapedesis. 
Thereafter, HIV-1 in these cells may escape to infect other CNS resident cells. This mode of 
trafficking is also known as the “Trojan-horse mechanism” (C). Adapted from Strazza et al (2011) 
(205).   
 
1.10.2 Compartmentalization of HIV-1 in the CNS 
HIV-specific antibodies identified in the central nervous system (CNS), and not the periphery, in 
advanced disease suggested there was active infection of the brain by HIV-1, but it was not known 
when, how or why the virus enters the CNS (213). Early studies found HIV-1 antigens in 
individuals who had not yet seroconverted showing that HIV-1 was able to infiltrate the CNS 
soon after primary infection and persists in all stages of diseases (214). While it was recognized 
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that people living with HIV frequently developed HIV-associated neurological disorders (HAND) 
including HIV-associated dementia (HAD), pathogenic mechanisms to explain the observation 
were minimal. Autopsies revealed that HIV-1 could infect tissues of the brain (215-217). More 
specifically, the virus was confirmed to have the capacity to infect and replicate in the choroid 
plexus, astrocytes, neurons and microglia in chronic stages of disease before AIDS (218-222).  
Because isolating HIV-1 from the brain-tissues of living study participants is an invasive 
procedure and not possible, HIV-1 in the cerebrospinal fluid (CSF) is studied as a surrogate of 
CNS viruses instead (223-231). HIV-1 was observed to exhibit a CNS-specific replication or 
biological phenotype, but it was not clear why, when and how the virus accomplished this form 
of compartmentalization (232). Individuals with HAND were found to have elevated CSF HIV 
RNA levels (223, 233), and a discordant biological phenotype of HIV-1 between plasma and CSF, 
suggesting that HIV may evolve differently in the CNS (223). The concept of CNS 
compartmentalization of HIV-1 was proposed by Ellis et al (1997). They proposed that in the pre-
AIDS period HIV-1 is trafficked to the CNS through mononuclear cells and this is how the viral 
load seen in the CSF is determined. Additionally, in AIDS, independent CNS replication of HIV-
1 is unmasked when the CD4+ target cells are depleted, and this is linked to the HAND observed 
(233). A number of studies thereafter showed that peripheral blood-derived viruses can be 
genetically different to viruses in the CSF or brain-tissue (226-228, 231, 234, 235), confirming 
that an enrichment of compartmentalized CNS-exclusive variants arise when individuals present 
with HAD. Furthermore, R5 variants were responsible for the development of HAD in the 
majority of individuals, while it was unclear whether CXCR4-using variants contributed the 
development of HAD, as they were rarely identified in the CSF or CNS compartment (224).  
Cells of the monocyte-macrophage lineage or immune pressures in the brain were thought to 
constrain the genetic and functional diversity of HIV-1 in a way that is different to other cells 
(236, 237). It was proved that some well-established R5 variants specific to the CNS may have 
the added ability to amplify themselves clonally in MDMs, which express low densities of CD4 
on their surface, while other variants can only infect lymphoid-like cells which express high 
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densities of CD4 on their surface (194, 238, 239). In individuals with neurological deterioration 
it is likely that cells of the myeloid lineage replace cells of the lymphoid lineage as the dominant 
host for HIV-1 replication in the CNS, especially in the context of limited pleocytosis and CD4 
counts (239).  
Few studies have focused on the neurotropism of HIV-1C and its ability to infect myeloid-like 
cells. One study revealed that half of children under the age of 18 month may have incomplete 
equilibration of viral variants between peripheral blood and the CNS compartment, whereas half 
of children older than 18 months of age had compartmentalized viral variants in the CNS. HIV-
1C is introduced into the CNS compartment early after primary infection or is recruited to the 
CNS later during the course of infection. Furthermore, the authors proposed four different ways 
HIV-1 may be compartmentalized in the CNS: Firstly, the virus may be trafficked to the CNS 
early after primary infection with little selectivity. Secondly, certain HIV-1 variants may be 
selected to replicate in the CNS early after primary infection while others are not. Thirdly, limited 
or minor compartmentalization in the CNS may arise early after primary infection without a 
significant increase of viral load in that compartment. Lastly, import of virus into the CNS may 
lead to distinct compartmentalization of variants which are adapted to replicate in myeloid-like 
cells, with an increased viral load concurrently (228). An extension of the study of HIV-1 
neurotropism by the same authors, designed to factor in the effects of pleocytosis, revealed four 
states to describe the viral populations between the blood and CNS in early primary infection 
(Figure 1.12). The first state observed was minimal CNS replication of HIV-1 and pleocytosis; 
viral populations in blood were similar to those in the CNS, and any independent viral replication 
was undetectable. The second state observed was equilibration of viral variants between 
compartments, high virus copy numbers in both compartments and high levels of pleocytosis: the 
source of virus in the CNS was CD4+ T-cells trafficked from the blood. The third state observed 
was clonally amplified HIV-1 in the CNS with low genetic diversity; R5 virus was introduced 
recently into the CNS but relied on cells expressing high amounts of CD4 to expand. The last 
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state observed was persistent CNS replication of complex viral populations which are 
compartmentalized (231).  
 
Figure 1.12: The relationship of viral populations between the blood and CNS 
compartments in early primary infection. 
The blood and CSF/CNS compartments are shown; blood plasma and CSF/CNS-produced HIV-
1 variants are red and blue color, respectively; solid and dotted circles represent CD4+ T-cells 
producing detectable and undetectable HIV-1 populations, respectively, and arrows show the 
movement of viral variants between compartments. The first state observed is when the viral load 
in the CSF/CNS compartment is low, pleocytosis is low and the viral variants in both 
compartments are similar (A). The second state observed is when viral populations between 
compartments are equilibrated and pleocytosis is high. Viruses seen in the CSF are likely 
produced from CD4+ T-cells infiltrating the CSF, and local CNS replication of virus is obscured 
if occurring (B). The third state observed is when low diversity of clonally amplified HIV-1 in 
the CSF/CNS compartment persists. Low diversity is shown as viruses with a single shade of blue 
color (C). The fourth and last state is when genetically complex HIV-1 populations in the CNS 
persist; ongoing local viral replication is observed, and the viral population is diverse, shown as 
variants with different shades of blue color (D). Reproduced from Sturdevant et al (2015) (231).  
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1.10.3 Cryptococcal meningitis (CM) affects compartmentalization of HIV-1  
Opportunistic infections of the CNS infections affect HIV-1 RNA concentrations in the CNS. 
Studies of individuals with HIV-1 and CM co-infection revealed an association between HIV-1 
RNA concentrations in the CSF and the number of CSF white blood cells (240). However, 
because the HIV-1 RNA concentration in the CSF did not correlate with that of the plasma, this 
was indication of intrathecal HIV-1 replication, and that the blood and CNS compartments may 
behave differently (241, 242). Although it was not clear initially why there was a lymphocytic 
infiltrate into CNS, it was thought that intrathecal cytokine production may recruit already 
infected lymphocytes into the CNS and enhance local inflammation. The consequences of that 
would be that more lymphocytes would be recruited into the CNS, further breakdown of the BBB 
and increased viral replication. Subsequent studies confirmed that pro- and anti-inflammatory 
cytokines produced locally in the CNS contribute to lymphocytic infiltrates into the CNS (243). 
A recent study shed more light on compartmentalized immune responses in matched blood and 
the CNS of patients with CM. It was shown that natural killer (NK) cells and monocytes in the 
CSF have different markers of activation and function to those in the blood. Immunoregulatory 
NK cells in the CSF were in higher proportions than in blood, suggesting that they there were 
recruited to the CNS by pro-inflammatory cytokines (244). Further evidence that the CNS is a 
unique environment relative to the blood is the observation that HIV-1 RNA concentration in the 
CSF is significantly lower than in peripheral blood in patients with CM. However, it is unclear 
whether this is because the viral genotypes and phenotypes in the two compartments are different 
(245).  
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Core research problems and their significance 
The CNS is an anatomical compartment distinct from other compartments of the body. The 
immunological milieu and targets for HIV-1 in the CNS are different compared to the blood. The 
majority of the studies of HIV-1 genetic or phenotypic compartmentalization between the blood 
and CNS were focused on HIV-1B to understand HAND in the absence of co-infections (223, 
226, 229, 235, 239, 246-250). Furthermore, two studies of HIV-1C compartmentalization 
between the blood and CNS were focused on young children with HAND (228) and individuals 
in the chronic stage of HIV-1 disease (160). Even less is known about the effect of co-infection 
on HIV-1 compartmentalization, though one case study suggested that CNS co-infection with 
varicella-zoster virus may increase the replication of HIV-1 (251). In the context of HIV-1 and 
CM co-infection, it has been shown that HIV-1 RNA concentrations between the plasma and CSF 
may be compartmentalized (242, 245). However, it is not clear whether this is due a difference of 
HIV-1 genotypes and/or phenotypes between the blood and CNS compartments.  
Given that Cryptococcus neoformans, the fungal pathogen which causes CM, is capable of 
crossing the blood-brain barrier (BBB) and may alter the immunological environment in the CNS, 
this may affect the trafficking of HIV-1 between the blood and CNS as well. Therefore, clarifying 
whether or not CM patients have compartmentalized HIV-1C will be important for understanding 
the role of co-infections in HIV-1 compartmentalization and informing the therapeutic 
management of HIV-1 in the CNS.  
 
The switch of major coreceptor usage by HIV-1, from exclusive usage of CCR5 to the additional 
or exclusive usage of CXCR4, usually occurs in the chronic stage of infection for individuals 
harboring HIV-1B (165, 167), and the switch is associated with an accelerated rate of disease 
progression (166, 168). There is no consensus on the prevalence of HIV-1C major coreceptor 
switching, although it appears to be less frequent than in HIV-1B. The switch of major coreceptor 
usage has been observed largely in individuals with end-stage HIV disease; when they already 
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have a low CD4+ T-cell count and an AIDS-defining illness (116, 172, 173). However, other 
studies have recorded rare switching occurring (170, 171, 252, 253), while some noted an absence 
of coreceptor switching in end-stage disease (72, 169). Therefore, the context and requirements 
of HIV-1C coreceptor switching are unclear. If usage of CXCR4 by HIV-1C is on the rise, then 
an accurate prevalence of individuals with CXCR4-using HIV-1C is important as it will indicate 
the number of individuals who are likely to progress to AIDS faster, and will inform which 
individuals are eligible for maraviroc, a therapeutic CCR5 antagonist.  
HIV-1C is capable of using the major coreceptors CCR5 and CXCR4 individually or in 
combination (74, 77, 116, 173), and may even use alternative coreceptors (116, 146, 147, 158-
160, 170). The usage of alternative coreceptors by HIV-1C has been frequently reported in 
individuals with chronic or end-stage disease, however, those were viruses were not from 
peripheral blood predominantly. An evaluation of the major and alternative coreceptor usage of 
HIV-1 in the CNS revealed that HIV-1C uses CCR5 predominantly while it may also have a 
preference for the CXCR6 coreceptor (160). However, it is not clear which receptors other than 
CCR5 or CXCR6 may be used by HIV-1C in the CNS. CCR3 is expressed on the surface of 
microglia and macrophages in the CNS, and may be used by HIV-1B isolates (152-154). 
However, it is unclear whether CCR3 is used by HIV-1C isolated from the CNS compartment. 
Evaluating the usage of this alternative coreceptor by HIV-1C will improve our understanding of 
HIV-1 phenotypes in end stage disease and the pathogenesis of HIV-1C in the CNS compartment.   
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The motivation for this research study 
A comprehensive genotypic and phenotypic characterization of HIV-1C in individuals presenting 
with CM is lacking. Here, the overall aim of our research study was to characterize the genotypic 
and phenotypic properties of HIV-1C circulating in cerebrospinal fluid and plasma of 
antiretroviral therapy naïve individuals presenting with CM. We designed our study to contribute 
to the understanding of the following: 
 HIV-1C genotypes, and gene flow between the peripheral blood and CNS compartments. 
 HIV-1C major coreceptor usage phenotypes in end-stage disease, and the eligibility of 
individuals for using maraviroc. 
 The usage of an alternative coreceptor, CCR3, by HIV-1C in peripheral blood and CNS. 
For the genotypic characterization of HIV-1C, we had the following sub-aims: 
1. To determine whether there was genetic intermixing of HIV-1C variants between the 
peripheral blood and CNS compartments. 
2. To determine whether cART naïve patients living with HIV-1C and CM are eligible for 
treatment with the CCR5 antagonist maraviroc, which is now in clinical use only for 
individuals with R5 viruses only.  
For the phenotypic characterizations of HIV-1, we had the following sub-aims: 
1. To confirm the functionality and major coreceptor usage of HIV-1C in CM patients. 
2. To determine the accuracy of CPAs which predict the major coreceptor usage of HIV-
1C. 
3. To evaluate the usage of an alternative coreceptor by HIV-1C in end-stage disease. 
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The organization of the thesis 
This thesis is organized in the following way: 
1. Chapter 1 is the introduction of the thesis. It includes the background of topics relevant 
to this thesis, the aims and objectives for our studies.  
2. Chapter 2 is the first results chapter. It was structured in accordance with the 
specifications of the journal it was submitted to for publication.  
3. Chapter 3 is the second results chapter.  
4. Chapter 4 is the third results chapter.  
5. Chapter 5 is the discussion for the three results chapters.  
6. Chapter 6 is the conclusions section for the three results chapters. 
7. Chapter 7 consists of recommendations relating to the results chapters. 
8. Chapter 8 consists of the references used for the introduction and discussion chapters.  
9. Chapter 9 consists of appendices.  
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The background and literature review presented in Chapter 1 highlighted that the CNS may 
provide a unique tissue reservoir for HIV-1, and that the trafficking of viral variants from the 
blood to the CNS has implications for disease persistence and progression. Additionally, it was 
indicated that the frequency reported of CXCR4 usage by HIV-1C is inconsistent, though it may 
be high in individuals with end stage disease. In Chapter 2, we present a study conducted to 
establish whether or not HIV-1C variants in peripheral blood are genetically segregated from 
those in the CNS of individuals with CM. Additionally, we provide an estimated frequency of 
CXCR4-using HIV-1C in individuals with end stage infection. 
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Chapter 2: Individuals with HIV-1 subtype C infection and cryptococcal 
meningitis exhibit viral genetic intermixing of HIV-1 between plasma and 
cerebrospinal fluid, and a high prevalence of CXCR4-using variants 
 
Katlego Sojane,1 Richard T. Kangethe,1 Christina C. Chang,2 Mahomed-Yunus S. Moosa,3 Sharon 
R. Lewin,2,4 Martyn A. French,5,6 and Thumbi Ndung’u1,7,8,9 
 
1HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela 
School of Medicine, University of KwaZulu-Natal, Durban, South Africa; 2Department of 
Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia; 3Department 
of Infectious Diseases, King Edward VIII Hospital, University of KwaZulu-Natal, Durban, South 
Africa; 4The Peter Doherty Institute for Infection and Immunity, University of Melbourne and 
Royal Melbourne Hospital, Melbourne, Australia; 5Medical School and School of Biomedical 
Sciences, University of Western Australia, Perth, Australia; 6Department of Clinical 
Immunology, Royal Perth Hospital and PathWest Laboratory Medicine, Perth, Australia; 7Africa 
Health Research Institute, Durban, South Africa; 8Ragon Institute of MGH, MIT and Harvard 
University, Cambridge, MA 02139, USA; 9Max Planck Institute for Infection Biology, Berlin, 
Germany. 
 
Running title: HIV-1 env in cryptococcal meningitis patients 
Keywords: Cerebrospinal fluid, cryptococcal meningitis, HIV-1, plasma.  
39 
 
2.1 Abstract 
The genotypic properties of HIV-1 subtype C in individuals presenting with cryptococcal 
meningitis (CM) are not well established. Employing single-genome amplification as well as bulk 
PCR, cloning and sequencing strategies, we evaluated the genetic properties of HIV-1 subtype C 
env in 16 antiretroviral therapy naïve study participants with CM. Eleven of the 16 participants 
had matched blood plasma and cerebrospinal fluid (CSF) evaluated, with the rest having either a 
plasma or CSF sample evaluated. Before antiretroviral therapy initiation, matched plasma and 
cerebrospinal fluid-derived env sequences of all 11 participants displayed genetic intermixing 
between the two compartments. Overall, seven of the 16 (~43.8%) participants harbored CXCR4-
using variants in plasma and/or CSF, according to coreceptor usage prediction algorithms. This 
study suggests that HIV-1 subtype C genetic intermixing between peripheral blood and the central 
nervous system is common in individuals presenting with CM, and that CXCR4 usage is present 
in one or both compartments in approximately 44% of individuals.  
  
  
40 
 
2.2 Introduction 
To initiate infection, the human immunodeficiency virus type 1 (HIV-1) attaches itself to a target 
cell by binding to cell-surface CD4 and a chemokine receptor, usually CCR5 or CXCR4 (1-3). 
The ability of HIV-1 to use a particular coreceptor for entry is determined primarily by the 
properties of the envelope protein (Env) V3 loop (4, 5), though determinants outside of the V3 
loop may also contribute (6-9). Variants which use CCR5 only (R5-tropic) predominate early in 
infection generally, however, variants with expanded coreceptor usage ability may arise over time 
(10, 11). Approximately 50% of individuals infected with HIV-1 subtype B (HIV-1B) have 
variants which use CCR5 and CXCR4 (R5X4-tropic) or CXCR4 only (X4-tropic) during the 
chronic stage of disease, and the emergence of these variants is associated with an accelerated 
decline of CD4+ T-cell count (12, 13). In contrast, the prevalence of CXCR4 usage for entry by 
HIV-1 subtype C (HIV-1C) is unclear. Some studies have reported an absence or low prevalence 
of CXCR4 usage by HIV-1C (14-18), while others have detected 15% to 30% of individuals with 
advanced or end-stage disease harboring CXCR4-using variants (19-21). Further studies are 
needed to clarify the frequency and circumstances of CXCR4 usage by HIV-1C isolates, so that 
individuals’ eligibility for use of coreceptor blocking drugs such as maraviroc, a CCR5 antagonist, 
may be accurately determined. 
HIV-1 is detectable in the central nervous system (CNS) in primary infection (22-24), where its 
presence may ultimately cause HIV-associated neurological disorders (25, 26). Studies of CNS 
compartmentalization of HIV-1 are limited because obtaining brain biopsies is not possible, 
however, the cerebrospinal fluid (CSF) has been used often as a surrogate of the CNS 
compartment (27-29). Early studies of HIV-1B env genes from matched plasma and CSF showed 
that variants unique to the CSF could arise (30), and that this genetic compartmentalization of 
variants was most pronounced in individuals with HIV-associated dementia (HAD) (31, 32). Later 
studies combining genotypic and/or phenotypic analyses confirmed clonal amplification of HIV-
1B and HIV-1C variants in the CNS, indicating that the CNS can act as a compartment of unique 
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HIV persistence relative to peripheral blood (24, 33, 34). In a limited number of studies, a 
discordant entry phenotype of HIV-1B between the blood and CNS was reported in individuals 
with chronic stage HIV-1 disease (27, 35-37). It is unclear how common genotypic discordance 
of HIV-1C between plasma and CSF is in individuals with advanced HIV infection and a co-
infection.  
Individuals harboring R5 HIV-1 only are eligible for combination antiretroviral therapy (cART) 
containing maraviroc, a CCR5 antagonist, while those harboring R5X4 or X4-tropic viruses are 
precluded from using this drug (38). There are multiple genotypic tools or algorithms used to 
determine the coreceptor usage of HIV-1 in order to determine eligibility for use of maraviroc 
(39). One approach is to use coreceptor usage prediction algorithms (CPAs) such as Geno2pheno, 
WebPSSM and PhenoSeq which utilize the whole V3 loop sequences of HIV-1 Envs to predict 
whether a virus will be R5 or CXCR4-using (using CCR5 and CXCR4, or CXCR4 alone) (40-
42). CPAs, therefore, are attractive diagnostic tools, as they are relatively inexpensive and less 
laborious to use than determinations by in vitro phenotypic assays.  
HIV-related cryptococcal meningitis (CM) is an acquired immune deficiency syndrome (AIDS) 
defining illness which is associated with high acute mortality rates, and is most prevalent in sub-
Saharan Africa (43-45). Previous studies by our group revealed that compartmentalization of 
immune responses may arise between the blood and CNS compartment in individuals with CM, 
where pro-inflammatory natural killer cells, non-classical monocytes, chemokines and cytokines 
are enriched in CSF relative to blood (46). We were interested in establishing whether or not HIV-
1 genetic properties are compartmentalized in individuals with HIV-related CM. We hypothesized 
that localized inflammation in the CNS caused by Cryptococcus neoformans (or its antigens) 
provides an immunological milieu that recruits HIV-1C variants into the CNS, causing viral 
genetic mixing between peripheral blood and the CNS. We therefore explored whether CM was 
associated with HIV-1C genetic compartmentalization between blood plasma and the CSF or not, 
and whether in this setting there was evidence of CXCR4 usage by HIV-1 subtype C variants.  
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2.3 Materials and methods 
2.3.1 Study participants 
The participants for this sub-study were part of a larger prospective clinical study of 
Cryptococcosis‐associated immune reconstitution inflammatory syndrome (C‐IRIS) conducted in 
Durban, South Africa between August 2009 and September 2011, as described in detail elsewhere 
(47). Written informed consent was provided by each participant or their next-of-kin. The ethics 
review boards of the University of KwaZulu-Natal (reference number BF053/09), Monash 
University (2009001224) and University of Western Australia (RA/4/1/2541) granted ethics 
approval for the study. For the current study, 16 antiretroviral therapy naïve participants infected 
with HIV-1 and presenting with CM for the first time at the clinic were randomly selected based 
on the criteria of detectable HIV-1 RNA in the plasma and CSF according to the COBAS TaqMan 
HIV-1 test (Hoffmann-La Roche, Basel, Switzerland) with a lower limit of 34 copies/mL, a CD4+ 
T-cell count less than 200 cells/µL, and either a positive CSF cryptococcal antigen (CrAg) or 
Indian ink test result.  
 
2.3.2 Plasma and CSF sample processing 
The cell-free HIV-1 RNA levels in matched plasma and CSF samples were measured in the same 
polymerase chain reaction (PCR) assay run using the COBAS TaqMan HIV-1 test as described 
previously (48). Routine cell count analyses including the enumeration of white blood cell subsets 
in the CSF and CD4+ T-cells in peripheral blood were performed by standard clinical laboratory 
assays in an accredited laboratory (47). 
 
2.3.3 RNA extraction and the synthesis of cDNA 
The extraction of HIV-1 RNA from the plasma and CSF was performed using the QIAamp Viral 
RNA Mini kit (Qiagen, Dusseldorf, Germany) according to the manufacturer’s instructions. 
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SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA) was used for cDNA synthesis 
as previously described (49). Briefly, 10 µL of extracted RNA was added to a mixture of 1 mM 
of deoxynucleoside triphosphates and 2 µM of primer OFM19 (5’-
GCACTCAAGGCAAGCTTTATTGAGGCTTA-3’; HXB2 positions 9,604-9,632). The mixture 
was first heated to 65 °C for five minutes and cooled to 4 °C for one minute. The following 
reagents were combined and then added to the initial mixture for a final volume of 20 µL per 
sample: 1X reverse transcriptase (RT) buffer, 0.1 M dithiothreitol, 40 units of RNaseOUT 
(Invitrogen), and 200 units of SuperScript III Reverse Transcriptase enzyme. The complete 
reaction mixture was incubated at 50 °C for 60 minutes, 55 °C for 60 minutes to commence cDNA 
synthesis, incubated at 70 °C for 15 minutes to inactivate the reverse transcriptase enzyme, and 
cooled to 4 °C to end cDNA synthesis.  
 
2.3.4 Single genome amplification of plasma and CSF-derived variants 
Unique viral variants were purified by single-genome amplification (SGA) and Sanger 
sequencing as described previously (49). Synthesized cDNA was serially diluted, and a minimum 
of 10 PCR reactions for each dilution were performed. The dilution which presented less than or 
equal to 30% positive amplification reactions represented the end-point dilution, where each 
positive amplification reaction contained a unique viral template (50). Both rounds of PCR were 
performed using the Platinum Taq DNA Polymerase High Fidelity (Invitrogen) as described 
previously (49, 51). The first round of PCR included the forward primer VIF1 (5’-
GGGTTTATTACAGGGACAGCAGAG-3’; HXB2 positions 4,900-4,923), reverse primer 
OFM19, and 1 µL of diluted cDNA. The second round of PCR included forward primer ENVA 
(5’-GCTTAGGCATCTCCTATGGCAGGAAGAA-3’; HXB2 positions 5,945-5,982), reverse 
primer ENVN (5’-CTGCCAATCAGGGAAGTAGCCTTGTGT-3’; HXB2 positions 9,145-
9,171) and 2 µL of first round PCR product. The cycling conditions for both rounds of PCR were 
as follows: 94 °C for 4 minutes; 35 cycles of 94 °C for 15 seconds, 55 °C for 30 seconds, 68 °C 
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for 4 minutes; a final extension step of 68 °C step for 20 minutes followed by a hold at 4 °C. 
Positive PCR reactions were detected by agarose gel electrophoresis, and amplicons from end-
point dilution reactions were sequenced directly from the second round PCR products.  
 
2.3.5 Bulk PCR and cloning 
Using a modified, nested bulk PCR and cloning protocol, 2.1 kb KpnI-to-BamHI env gene 
fragments were amplified from undiluted cDNA as described previously (52-54). Briefly, the 
forward VIF1 primer, reverse OFM19 primer, the Platinum Taq DNA Polymerase High Fidelity 
(Invitrogen), and 1 µL of undiluted cDNA were included in the first round PCR reaction mixture. 
In the second round of PCR, the forward Env-KpnI primer (5'-
GTCTATTATGGGGTACCTGTGTGG-3'; HXB2 positions 6,336-6,359), reverse Env-BamHI 
primer (5'-GCTAAGGATCCGTTCACTAATCGT-3'; HXB2 position 8,463-8,485), the Phusion 
High-Fidelity DNA polymerase (New England Biolabs, Ipswich, MA), and 2 µL of PCR product 
from the first round of PCR were included. PCR products from second round reactions were 
analyzed by agarose gel electrophoresis, and detected amplicons were gel purified. Purified 
amplicons were cloned into the pSVIII-Env plasmid for the purposes of sequencing (52, 54, 55). 
 
2.3.6 Sequencing of HIV-1 env genes 
SGA-derived amplicons from second round PCR products and recombinant pSVIII-Env vectors 
were sequenced using the ABI Prism Big Dye Terminator Version 3.1 cycle sequencing kit 
(Applied Biosystems, Waltham, MA), incorporating multiple forward and reverse primers that 
covered the entire HIV-1 env gene (56). Sequences were resolved using the ABI 3130 XL genetic 
analyzer and contigs composing env genes were assembled and manually edited with Sequencher 
version 5.4.1 (Genecodes, Ann Arbor, MI). Sequencing chromatograms with multiple 
overlapping peaks were discarded along with duplicate sequences.  
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2.3.7 Phylogenetic analyses 
All participant-derived env genes were aligned with a panel of reference sequences from different 
subtypes available in the Los Alamos National Laboratory HIV database 
(https://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html) using Clustal W. With MEGA 
7 software (57), a neighbor-joining phylogenetic tree of 1,000 bootstrap replicates was 
constructed using the V1 to V5 env gene regions to determine the subtype, detect inter-participant 
sequence contamination, and identify inter-compartment mixing of HIV-1 variants. Evolutionary 
distances were computed using the maximum-likelihood composite method, where all positions 
containing gaps or missing data were excluded in the analysis as described previously (15). 
 
2.3.8 Compartmentalization analyses 
For two participants, CM112 and CM089, there were a minimum of 10 SGA-derived sequences 
from the plasma and CSF each, allowing for evaluation of the degree of HIV-1 genetic 
compartmentalization between the two compartments as described previously (33, 58). 
Maximum-likelihood phylogenetic trees showing the intra-participant phylogenetic relatedness 
of plasma and CSF-derived env genes were generated using MEGA 7 (57) and PhyML software 
(59) with the following parameters: HK85 nucleotide substitution model, four substitution rate 
categories, a transition/transversion ratio of four, estimated gamma distribution parameter and 
1,000 bootstrap replicates. Compartmentalization of CSF sequences was determined using the 
Slatkin-Maddison (tree-based) and Hudson nearest-neighbor tests (distance-based) with 10,000 
permutations, in HYPHY as previously described (33, 58, 60). A p-value equal to or lower than 
0.05 signified CSF compartmentalization of sequences. 
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2.3.9 Prediction of coreceptor usage 
The publicly available coreceptor usage prediction algorithms (CPAs), Geno2pheno with a false 
positive rate (FPR) of 5% (http://coreceptor.bioinf.mpi-inf.mpg.de/), WebPSSM subtype C sinsi 
(WebPSSM; https://indra.mullins.microbiol.washington.edu/webpssm) and PhenoSeq 
(www.burnet.edu.au/phenoseq) were used to predict the major coreceptor usage of participant -
derived sequences (40-42). All three tools predict the major coreceptor usage of Env V3 
sequences, however, they are not optimized to distinguish R5X4-tropic variants from X4-tropic 
variants. Here, we designated variants as R5 if they were predicted to use CCR5, and R5X4/X4 
if they were predicted to use CXCR4 in combination with CCR5 or alone. Where the algorithms 
differed in predictions, we characterized an Env as R5 or R5X4/X4 based on two concordant 
algorithms.  
 
2.3.10 Identification of N-linked glycosylation sites in the Env V3 loop sequences 
Using the N-GlycoSite tool 
(https://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html), the location and 
number of putative N-linked glycosylation sequons (tripeptide N-X-S and N-X-T, where X is any 
amino acid except proline) in V3 loop sequences was recorded (61). 
 
2.3.11 Net charge calculation 
Positively charged amino acids (lysine, arginine, and histidine) were scored as +1, and negatively 
charged amino acids (aspartate and glutamate) were scored as -1. The net charge of the Env V3 
was the sum of all positive and negative charges within the V3 sequence. 
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2.3.12 Statistical analyses 
Two-tailed, unpaired nonparametric t-tests were performed using GraphPad Prism version 5 for 
Windows (GraphPad Software, San Diego, CA) unless otherwise stated.  
 
2.4 Results 
2.4.1 Clinical features of individuals harboring HIV-1 and presenting with CM 
The detailed demographic and clinical characteristics of HIV-1 infected individuals with CM in 
the parent study have been described in detail elsewhere (47). Here, we randomly selected eight 
males and eight females infected with HIV-1 and presenting with CM, with matched plasma and 
CSF samples available in our laboratory for HIV-1 genotypic analyses. The samples were 
collected prior to initiation of cART. Demographic and clinical characteristics of these study 
participants are summarized in Table 2-1. The median age of the participants was 29.5 years 
(range: 23-45), with no significant difference between the median age of males and females (p = 
0.46), and the median CD4+ T-cell count was 27.5 (interquartile range: 10-72 cells/µL). The 
median plasma and CSF HIV-1 viral load of the participants were 5.1 (interquartile range: 4.72-
5.2) log10 copies/mL and 4.73 (range: 4.3-4.7) log10 copies/mL, respectively, and were not 
significantly different (p = 0.13). There was no significant difference between male and female 
plasma HIV-1 viral load (p = 0.23), and no significant difference between male and female CSF 
HIV-1 viral load (p = 0.88).  Two participants, CM032 and CM117, did not have detectable white 
blood cells in the CSF, whereas all other participants exhibited pleocytosis (>5 CSF white blood 
cells/µL). We observed a positive correlation between the CD4+ T-cell count and white blood cell 
count in the CSF (spearman r = 0.7, p = 0.0026).  
 
  
48 
 
Table 2-1: Demographic and clinical characteristics of the study participants. 
IDa Age Sex CD4 countb Plasma VLc CSF VLd CSF WBCe 
CM019 45 M 7 5.15 4.33 28 
CM021 30 F 134 4.34 4.34 40 
CM029 33 F 121 5.22 5.99 424 
CM032 34 F 5 4.94 2.52 0 
CM041 26 F 58 4.51 4.93 102 
CM050 23 F 16 4.92 4.8 6 
CM052 24 F 172 4.62 4.83 36 
CM054 23 M 7 5.2 4.2 14 
CM070 25 M 11 5.04 4 18 
CM089 27 M 114 5.67 5.85 154 
CM094 29 F 35 5.15 4.03 84 
CM098 40 M 14 4.76 5.27 66 
CM108 27 M 20 5.16 5.02 28 
CM112 34 F 39 5.52 5.62 6 
CM117 38 M 1 5.72 4.66 0 
CM132 34 M 53 4.58 4.43 38 
aThe identification number of the study participant. bThe CD4+ T-cell count was recorded as 
cells/µL. c,dThe cell-free HIV-1 RNA viral load (VL) in plasma and CSF was recorded as log10 
copies/mL. eThe CSF white blood cell (WBC) count was recorded as cells/µL. 
 
2.4.2 The phylogenetic relationships of HIV-1 variants  
We amplified and sequenced a total of 251 unique env genes from the plasma and CSF 
compartments of 16 participants, using either single-genome amplification (SGA) and 
sequencing, or bulk PCR, cloning and sequencing methods. The number of sequences generated 
per compartment of each participant using the two methods is summarized in Table 2-2. 
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Phylogenetic analysis, performed as described in Materials and methods, revealed that all the 
sequences generated were subtype C. As expected, plasma and/or CSF sequences of each 
individual participant formed a unique cluster. All of the eleven participants with available 
matched plasma and CSF sequences had evidence of inter-compartment mixing of env sequences 
(Figure 2.1).  
Genetic compartmentalization between anatomical compartments is more accurately determined 
using SGA-derived sequences than bulk PCR-derived sequences, as the former limits or 
eliminates taq-induced recombination, nucleotide misincorporation, template resampling and 
cloning bias (49). We sought to establish whether there was genetic compartmentalization of HIV-
1C sequences between the plasma and CSF or not of two participants (CM089 and CM112) where 
we generated at least 10 sequences from both of their compartments by SGA. For both 
participants, inter-compartment mixing of env sequences was evident (Figure 2.2). The Slatkin-
Maddison test revealed seven and 10 inter-compartment migrations in participants CM089 and 
CM112, respectively. Additionally, neither CM089 nor CM112 demonstrated 
compartmentalization of env sequences (p-value 0.19, and 0.35 respectively). This result was 
confirmed with the Hudson nearest-neighbor test (p-value 0.34 and 0.58 for CM089 and CM112, 
respectively). 
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Table 2-2: The number of sequences generated from the plasma and CSF of the study 
participants. 
IDa Plasmab CSFc Total 
 Cloning SGA Cloning SGA  
CM019 11 17 1 0 29 
CM021 1 2 2 13 18 
CM029 0 0 5 6 11 
CM032 3 - 1 - 4 
CM041 - 4 - 0 4 
CM050 2 1 1 9 13 
CM052 3 6 3 11 23 
CM054 3 - 0 - 3 
CM070 5 - 0 - 5 
CM089 - 10 - 19 29 
CM094 0 - 3 - 3 
CM098 11 - 16 - 27 
CM108 9 - 8 - 17 
CM112 - 16 - 16 32 
CM117 12 - 9 - 21 
CM132 - 8 1 3 12 
Total     251 
aThe identification number of the study participant. b,cSequences were generated by the single-
genome amplification (SGA) and sequencing, or bulk PCR, cloning and sequencing method. 
Dashes indicate where we did not attempt to generate sequences for this sample using this method, 
and zeros indicate where we were unable to amplify cDNA before the sample was completely 
consumed or we could not amplify an env gene.  
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Figure 2.1: A neighbor-joining phylogenetic tree of participant-derived HIV-1 envelope 
gene sequences and a panel of reference sequences from different subtypes. 
All of the sequences from individual study participants share the same color branches, and 
reference subtype sequences have grey branches. Closed circles and triangles at the tip of each 
branch indicate predicted R5 and CXCR4-using plasma-derived sequences, respectively. Open 
circles and triangles indicate predicted R5 and CXCR4-using cerebrospinal fluid-derived 
sequences, respectively. No inter-participant mixing of sequences was observed, suggesting an 
absence of inter-participant sequence contamination. Furthermore, all of the participant-derived 
sequences clustered with reference subtype C sequences while all other reference sequence 
subtypes clustered together but separately from subtype C sequences.  
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Figure 2.2: A maximum-likelihood phylogenetic tree of HIV-1 subtype C envelope variants 
in study participant CM089 (A) and CM112 (B). 
Envelope gene sequences labeled with red and blue circles were derived from plasma and 
cerebrospinal fluid, respectively. Bootstrap values greater than 70% are shown at their respective 
nodes and the genetic distance scale bar reflects the number of nucleotide substitutions per site.  
 
2.4.3 Predicted coreceptor usage of HIV-1C in plasma and CSF  
To get better insight into the predicted coreceptor usage by HIV-1 subtype C variants in end-stage 
disease, we used three publicly available CPAs (Geno2pheno, WebPSSM and PhenoSeq) to 
generate a consensus prediction of the coreceptor usage of unique V3 sequences obtained in this 
study (Table 2-3). We also assessed whether predicted R5 variants predominate over CXCR4-
using variants in plasma and CSF samples (Figure 2.3). Assessing plasma samples first, we 
identified that seven of 14 (50%) participants harbored predicted R5 variants only, whereas one 
participant (7.1%) harbored only predicted CXCR4-using variants, and six participants (42.9%) 
harbored a combination of predicted R5 and CXCR4-using variants. Thus, predicted R5 variants 
featured in 13 participants (92.9%) and predicted CXCR4-using variants were detected in seven 
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participants (50%). When we assessed the predicted coreceptor usage profile of variants in the 13 
CSF samples, we identified that nine of 13 (69.2%) CSF samples harbored predicted R5 variants 
only, whereas two (15.4%) samples each harbored predicted R5 and CXCR4-using, and CXCR4-
using variants only. Therefore, predicted R5 variants featured in 11/13 (84.6%) samples, while 
predicted CXCR4-using variants were in 4/13 (30.8%) samples. These results suggest that 
predicted R5 variants predominate in plasma as well as CSF samples, and that CXCR4 usage is 
more common in plasma than in the CSF of HIV-1C infected participants with CM. Overall, seven 
of the 16 (~43.8%) participants included in this analysis harbored predicted CXCR4-using 
variants in plasma and/or CSF. 
We next assessed whether matched plasma and CSF samples have HIV-1C variants with 
concordant predicted coreceptor usage or not ( 
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). Seven of 11 (63.6%) participants with matched plasma and CSF sequences displayed 
concordant predicted coreceptor tropism of HIV-1C. A further two of 11 (18.2%) participants had 
discordance of predicted coreceptor tropism between plasma and CSF, where both predicted R5 
and CXCR4-using were detected in plasma but only predicted CXCR4-using or R5 variants were 
detected in CSF. In two of 11 (18.2%) participants (CM019 and CM032), the concordance of 
coreceptor usage between the plasma and CSF was indeterminate as we only had one CSF 
sequence compared to multiple plasma sequences. Our results show that concordant predicted 
coreceptor tropism between matched plasma and CSF compartments predominates over 
discordance in individuals with CM. 
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Table 2-3: V3 loop properties of HIV-1C envelopes. 
IDa Compart. Sequenceb G2P PhenoSeq PSSM-C Consensus Net charge Pos. 11, 25 PNGS Length 
CM019 
CSF CM019C.B (4:0) R5X4/X4 R5X4/X4 R5X4/X4 R5X4/X4 5 SD 0 37 
Plasma 
CM019P.2 (7:0) R5X4/X4 R5X4/X4 R5X4/X4 R5X4/X4 5 SD 0 37 
CM019P.B.3 (7:0) R5X4/X4 R5X4/X4 R5X4/X4 R5X4/X4 5 SD 0 37 
CM019P.E (5:0) R5 R5X4/X4 R5 R5 4 SD 1 35 
CM019P.I.2 (0:0) R5 R5 R5 R5 4 SD 1 35 
CM019P_SGA14 (0:0) R5X4/X4 R5X4/X4 R5X4/X4 R5X4/X4 6 SD 0 37 
CM021 
CSF CM021C.7.3 (2:14) R5 R5 R5 R5 3 SD 1 34 
Plasma CM021P_SGA22 (0:0) R5 R5 R5 R5 4 SD 1 35 
CM029 CSF 
CM029C.B.3 (0:5) R5 R5 R5 R5 4 SD 1 35 
CM029C.D.2 (0:1) R5 R5 R5 R5 4 SD 1 35 
CM029C.E.2 (0:1) R5 R5 R5 R5 5 SD 1 35 
CM029C_SGA01 (0:0) R5 R5 R5 R5 4 SD 1 35 
CM032 
CSF CM032C.6.4 (0:0) R5X4/X4 R5X4/X4 R5X4/X4 R5X4/X4 5 SR 1 35 
Plasma CM032P.10 (1:0) R5 R5X4/X4 R5X4/X4 R5X4/X4 4 SR 1 35 
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IDa Compart. Sequenceb G2P PhenoSeq PSSM-C Consensus Net charge Pos. 11, 25 PNGS Length 
CM032P.4 (0:0) R5X4/X4 R5X4/X4 R5X4/X4 R5X4/X4 9 HR 0 35 
CM041 plasma CM041P_SGA01 (3:0) R5 R5 R5 R5 4 SD 1 35 
CM050 CSF 
CM050C.5 (2:1) R5 R5X4/X4 R5 R5 5 GD 1 35 
CM050C_SGA01 (1:7) R5 R5X4/X4 R5X4/X4 R5X4/X4 6 S- 1 34 
CM052 
CSF 
CM052C.1 (5:7) R5 R5 R5 R5 3 SD 1 35 
CM052C_SGA04B (0:0) R5 R5 R5 R5 4 SD 1 35 
CM052C_SGA10B (2:4) R5 R5 R5 R5 4 SD 1 35 
Plasma 
CM052P_SGA03 (0:0) R5X4/X4 R5 R5X4/X4 R5X4/X4 4 SD 1 35 
CM052P_SGA06 (0:0) R5 R5 R5 R5 5 SD 1 35 
CM054 plasma CM054P.10.5 (2:0) R5 R5 R5 R5 4 SD 1 35 
CM070 Plasma 
CM070P.1 (1:0) R5X4/X4 R5X4/X4 R5X4/X4 R5X4/X4 7 SK 1 37 
CM070P.F.4 (1:0) R5 R5 R5 R5 5 SD 1 35 
CM070P.I.1 (0:0) R5X4/X4 R5X4/X4 R5X4/X4 R5X4/X4 8 NK 1 37 
CM089 CSF 
CM089C_SGA01 (5:13) R5 R5 R5 R5 4 SD 1 35 
CM089C_SGA07 (0:2) R5 R5 R5X4/X4 R5 5 SG 1 35 
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IDa Compart. Sequenceb G2P PhenoSeq PSSM-C Consensus Net charge Pos. 11, 25 PNGS Length 
CM089C_SGA16 (0:0) R5 R5 R5 R5 5 SG 1 35 
CM089C_SGA21 (3:0) R5 R5 R5 R5 4 SD 1 35 
Plasma 
CM089P_SGA05 (0:0) R5 R5 R5 R5 5 SD 1 35 
CM089P_SGA09 (0:0) R5 R5 R5 R5 5 SD 1 35 
CM094 CSF CM094C.11.2 (0:2) R5 R5 R5 R5 4 SD 1 34 
CM098 
CSF 
CM098C.1 (2:6) R5 R5X4/X4 R5 R5 3 SE 1 35 
CM098C.C.2 (0:0) R5X4/X4 R5X4/X4 R5X4/X4 R5X4/X4 3 SE 1 28 
CM098C.F.1 (5:0) R5 R5 R5 R5 5 SA 1 35 
CM098C.F.2 (0:1) R5 R5X4/X4 R5X4/X4 R5X4/X4 3 NE 1 35 
CM098C.H.1 (2:3) R5 R5 R5 R5 4 SA 1 35 
CM098C.J.4 (0:0) R5 R5 R5 R5 4 SA 1 35 
Plasma CM098P.A.1 (1:0) R5X4/X4 R5X4/X4 R5X4/X4 R5X4/X4 6 SK 1 37 
CM108 
CSF 
CM108C.7.12 (0:6) R5 R5 R5 R5 4 SD 1 35 
CM108C.8.9 (0:0) R5 R5 R5 R5 3 SD 1 35 
Plasma CM108P.1 (1:0) R5X4/X4 R5X4/X4 R5X4/X4 R5X4/X4 7 RD 1 35 
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IDa Compart. Sequenceb G2P PhenoSeq PSSM-C Consensus Net charge Pos. 11, 25 PNGS Length 
CM108P.D.5 (4:0) R5 R5X4/X4 R5X4/X4 R5X4/X4 5 SD 1 35 
CM108P.K.1 (1:0) R5 R5 R5X4/X4 R5 3 SD 1 35 
CM112 
CSF 
CM112C_SGA01 (11:11) R5 R5 R5 R5 4 SD 1 35 
CM112C_SGA11 (1:0) R5 R5 R5 R5 4 SD 1 35 
CM112C_SGA12 (0:1) R5 R5 R5 R5 4 SD 1 35 
CM112C_SGA13 (0:0) R5 R5 R5 R5 3 SD 1 35 
Plasma 
CM112P_SGA02 (1:0) R5 R5 R5 R5 3 SD 1 35 
CM112P_SGA10 (0:0) R5 R5 R5 R5 4 SE 1 35 
CM112P_SGA11 (0:0) R5 R5 R5 R5 4 SD 1 35 
CM117 CSF 
CM117C.A (12:7) R5 R5 R5 R5 2 SD 1 35 
CM117C.H.1 (0:0) R5 R5 R5 R5 2 SD 1 35 
CM132 
CSF 
CM132C.1 (3:2) R5 R5 R5 R5 3 SD 1 35 
CM132C_SGA01 (0:0) R5 R5 R5 R5 4 SD 1 35 
Plasma CM132P_SGA02 (4:0) R5 R5 R5 R5 4 SD 1 35 
aThe identification number of the study participant. bThe name of a unique sequence; the first and second number in the round brackets indicates the 
number of other sequences with the same V3 in plasma and CSF, respectively, of the participant. The predicted coreceptor usage was determined using 
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Geno2Pheno (G2P, with false positive rate of 5%), PhenoSeq and WebPSSM subtype C sinsi 
(PSSM-C). Consensus predicted tropism was determined based on the agreement of three, or 
two of three coreceptor usage prediction algorithms (CPAs). The amino acids occupying positions 
11 and 25 (Pos. 11, 25) were identified using PSSM-C; a dash indicates a gap at that position. 
The number of potential N-linked glycosylation sites (PNGS) in the V3 sequence was counted 
using N-GlycoSite. 
 
 
Figure 2.3:  The coreceptor usage in plasma and CSF samples. 
The overall predicted coreceptor usage, based on the consensus of three CPAs, in each of the 14 
plasma and 13 CSF samples across 16 participants was determined. The number of plasma and 
CSF samples harboring predicted R5, R5 and CXCR4-using, or only CXCR4-using variants are 
shown as stacked columns. 
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Table 2-4: The overall coreceptor usage of HIV-1 subtype C in the plasma and CSF of each 
participants with CM. 
IDa 
Coreceptor usage 
Plasma CSF 
CM019 R5, R5X4/X4 R5X4/X4 
CM021 R5 R5 
CM029 n.d R5 
CM032 R5X4/X4 R5X4/X4 
CM041 R5 n.d 
CM050 R5, R5X4/X4 R5, R5X4/X4 
CM052 R5, R5X4/X4 R5 
CM054 R5 n.d 
CM070 R5, R5X4/X4 n.d 
CM089 R5 R5 
CM094 n.d R5 
CM098 R5, R5X4/X4 R5, R5X4/X4 
CM108 R5, R5X4/X4 R5 
CM112 R5 R5 
CM117 R5 R5 
CM132 R5 R5 
aThe identification number of the study participant. The abbreviation “n.d” (not determined) 
indicates where were did not generate a sequence for the sample. 
 
2.4.4 Coreceptor usage determinants of HIV-1C Env 
Understanding the determinants of CCR5 or CXCR4 usage by HIV-1C is of clinical relevance 
given that a coreceptor antagonist, maraviroc, is FDA approved and available to individuals who 
harbor R5 variants only (38, 62). Previously, it was shown that HIV-1C CXCR4-using variants 
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have specific Env third variable loop (V3) properties which distinguish them from R5 variants. 
CXCR4-using HIV-1C variants have a V3 loop with greater amino acid variability, increased net 
charge, increased length, increased frequency of insertions, GPGQ crown motif substitutions, 
lower glycosylation site numbers, and charged residues at position 11 and/or 25 of the V3 (15, 
21, 63-66). Given that we identified a high prevalence of predicted CXCR4 usage by variants in 
this study, we sought to identify genetic properties of the major determinant of coreceptor usage, 
the V3 loop, which confer the ability to use CCR5 and/or CXCR4.  
We determined the following additional properties of the V3 of all the sequences generated in our 
study: the overall net charge, number of potential N-linked glycosylation sites (PNGS), residues 
at position 11 and 25, and length (Table 2-3). Although 251 unique env genes were available in 
this study, only 58 unique V3 sequences were identified and aligned with a reference South 
African HIV-1C sequence (Figure 2.4). The three CPAs all agreed on the predicted coreceptor 
usage for 48 of 58 (82.8%) unique V3 sequences, but in 10 of 58 (17.2%) instances only two of 
the three CPAs agreed with each other.  
As expected, the net charge of variants predicted to use CXCR4 (median 5; range 3-9) was 
significantly higher (p< 0.0001) than that of variants predicted to use CCR5 only (median 4; range 
2-5) (Figure 2.5). CXCR4-using variants of participants CM019, CM050 and CM052 did not have 
a positively charged residue at position 11 and/or 25 of the V3, whereas participants CM032, 
CM070, CM098 and CM108 harbored at least one variant with a histidine, arginine or lysine at 
position 11 and/or 25. No variant predicted as R5 possessed a charged residue at position 11 
and/or 25. This suggests that a charged residue at position 11 and/or 25 may be used to confer 
usage of CXCR4 for some CXCR4-using variants. Additionally, all CXCR4-using variants 
(except three from participant CM032 and one from CM052) had a positively charge residue at 
position 16 and/or 18 of the V3, within the crown motif. R5 variants maintained a GPGQ crown 
motif generally. 
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We then identified multiple sequences from participant CM019 and one from participant CM032 
which did not have PNGS and were predicted to use CXCR4, while every other sequence had one 
PNGS only at position 6 of the V3. This suggested that an absence of a PNGS in the V3 may 
contribute to the usage of CXCR4, but is not compulsory for CXCR4 usage. The range of V3 
length for CXCR4-using and CCR5 variants was 28-37 and 34-35 amino acids, respectively, both 
with a median of 35 (Figure 2.5).  
 
2.4.5 Rare mutation of the Env V3 detected 
The V3 loop of HIV-1 Env is a region important for function and maintains signature sequences 
according to subtype. The isoleucine at position 14 of the V3 (position 309 according to HXB2 
numbering or I309) is important for the structure of the V3 loop, and is conserved in 
approximately 99% of HIV-1C sequences (67). I309 also modulates the exposure of the CD4 
binding site (68). Notably, five unique V3 loop sequences of participant CM108 had a rare 
replacement of I309 with a phenylalanine residue, while every other sequence analyzed had an 
isoleucine at that position including the reference South African HIV-1C sequence (Ref.C.ZA) 
(Figure 2.4). The I309F residue was not specific to variants predicted to use CCR5, as it was 
present in variants predicted to use CXCR4 as well.  
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Figure 2.4: An amino acid sequence alignment of unique HIV-1C envelope V3 sequences 
from plasma and cerebrospinal fluid-derived viruses of antiretroviral therapy naïve 
individuals living with cryptococcal meningitis (CM). 
A reference South African HIV-1C envelope (Ref.C.ZA) V3 sequence was aligned with CM 
participant-derived sequences using MUSCLE (79). A star beside the sequence name indicates a 
variant that circulates in CSF, whereas the absence of a star beside the sequence name indicates 
a variant that circulates in plasma. The first and second number in the round brackets indicates 
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the number of identical V3 sequences in other variants circulating in plasma and CSF, 
respectively. The predicted coreceptor usage of each V3 sequence is indicated in square brackets: 
“R5” indicates it was predicted to use CCR5 only, and “R5X4/X4” indicates it was predicted to 
use CXCR4 in combination with CCR5 or alone. Amino acids identical to the reference sequence 
are shown as dots, disagreements are indicated as bold lettering, dashes indicate deletions, and 
the number to the right of the amino acid sequence indicates the length of the V3. The light blue 
bar shows position 6 of the V3 where potential N-linked glycosylation sites are located, the orange 
bar shows amino acids at position 11, the pink bar shows where two-amino acid insertions occur, 
the dark blue bar shows the crown motif sequences and the green bar shows amino acids at 
position 25 of the V3. 
 
 
Figure 2.5: The net charge and length of HIV-1 subtype C envelope V3. 
The net charge (A) and length (B) of the V3 sequence of 42 unique R5 (closed circles) and 16 
CXCR4-using (open circles) HIV-1C variants in this study was compared. The sequences from 
plasma and CSF sharing the same predicted tropism were pooled for this analysis. The red line 
indicates the median for each group. 
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2.5 Discussion 
Although others have studied HIV-1C env genes in individuals with advanced HIV disease and 
AIDS-defining illnesses (15, 17, 64, 69), genetic information of HIV-1C in matched blood and 
the CNS compartments of individuals with CM is sparse. In this study, we characterized the 
phylogenetic relatedness, and predicted coreceptor usage of plasma and CSF-derived HIV-1 
variants in individuals with CM. 
The sampling of HIV-1 from the CSF has been shown to be an adequate surrogate of sampling 
virus from the brain (29, 70). Equilibration, partial or complete, and compartmentalization of viral 
sequences between plasma and CSF have been described previously (24, 30, 33, 34). The 
occurrence of extreme genotypic compartmentalization of HIV-1 in the CNS, in particular, is 
suggestive of independent replication and evolution of viruses relative to the blood, and this is 
strongly associated with the development of neurocognitive impairment (31-33). The implications 
of equilibration or compartmentalization of HIV-1 sequences between blood and the CNS are 
unclear for individuals with co-infections. Here, we observed frequent intermixing of HIV-1C 
plasma and CSF-derived sequences in all 11 participants, such that plasma and CSF sequences 
did not form separate clusters but were phylogenetically interspersed among each other. 
Additionally, using the Slatkin-Maddison and Hudson nearest-neighbor compartmentalization 
algorithms on sequences from two participants CM089 and CM112, we observed an absence of 
compartmentalization of CSF-derived sequences in both participants. The majority of the 
participants in this study exhibited pleocytosis, a marker of CNS inflammation which is associated 
with HIV-1 trafficking between peripheral blood and the CNS (71), therefore it is probable that 
Cryptococcus neoformans and/or HIV-1C co-infection led to a breach of the blood-brain barrier 
which allowed movement of viruses between the peripheral blood and CNS compartments. 
Participants CM032 and CM117 did not display pleocytosis, however, though they had inter-
compartment mixing of sequences suggesting that pleocytosis is not a prerequisite for genetic 
intermixing between blood and the CNS. Because we did not evaluate longitudinal samples, we 
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also could not rule out a previous pleocytosis event that may had led to an absence of viral genetic 
segregation in these participants. Nevertheless, these results supported our hypothesis where we 
expected that inter-compartment mixing would arise in some individuals with CM. It is possible 
that immunological compartmentalization was a recent event associated with the development of 
active cryptococcosis, and therefore did not allow enough time for detectable independent viral 
evolution.  
R5 variants establish infection in the CNS compartment (23, 24), but R5, R5X4 and X4 have been 
isolated from the brain later in disease (72). We observed that concordance of predicted HIV-1 
coreceptor usage predominated in matched plasma and CSF samples. Our results were in 
agreement with other studies where phenotypic assays (35, 36) and CPAs (37) were employed, 
showing that concordance of HIV-1 coreceptor usage predominated but discordance of HIV-1 
between the plasma and CSF occurred in 10.9% to 35.7% of matched samples. Additionally, we 
showed that the plasma may harbor CXCR4-using variants in combination with R5 variants while 
the matched CSF harbors R5 variants only (participants CM108 and CM052), as described 
previously (36, 37). These results suggest that discordance of coreceptor usage between 
compartments was reflective of the functional compartmentalization of HIV-1, as others have 
shown that env sequences in the CNS may be compartmentalized (73). 
 
Previously, it was shown that CXCR4-using HIV-1C has greater amino acid variability, increased 
net charge, increased length, increased frequency of insertions, GPGQ crown motif substitutions, 
lower glycosylation site numbers, and charged residues at position 11 and/or 25 of the V3 relative 
to R5 variants (21, 63-66). In this study, we investigated whether the HIV-1C R5 and CXCR4-
using variants predicted by CPAs possessed the same determinants of coreceptor usage as variants 
from previous studies. We identified that many previously described V3 properties specific to 
HIV-1C R5 and CXCR4-using variants are consistent with variants in our study. In summary, the 
predicted CXCR4-using variants in our study had, compared to R5 variants, V3 sequences with 
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higher net charge, two amino acids insertions upstream of the crown motif, an absence of PNGS, 
a charged residue at position 11/and 25, and alterations of the GPGQ crown motif.  
 
Changes in position 14 of the V3 (position 309 according to HXB2 numbering) affect the structure 
of the loop (67), and the exposure of the CD4 binding site (68). We identified that sequences from 
participant CM108 possessed a change of the conserved isoleucine at V3 position 14 (I309) to 
phenylalanine (F309). Furthermore, the F309 residue was present in variants predicted as R5 and 
CXCR4-using, suggesting that this substitution was not unique to any particular coreceptor usage 
phenotype. Given that I309 was shown to influence the structure of the V3 and modulate the 
exposure of the CD4 binding site, it suggests that variants in participant CM108 may have a 
unique entry and immune evasion profile compared to variants with the I309 residue harbored by 
other individuals with CM. 
 
Reliable estimates of the prevalence of CXCR4 by HIV-1 are required to understand the evolution 
of the HIV-1C epidemic and to inform effective therapeutic interventions. HIV-1B has been 
shown to expand its usage of coreceptors in chronic and the end stages of disease (10-13). On the 
other hand, HIV-1C has been observed to switch major coreceptor usage less frequently (14, 15, 
19-21). In some cases, a complete absence of CXCR4 usage by HIV-1C was observed in 
individuals with advanced disease, suggesting that the ability to switch major coreceptors for this 
subtype is rare or not essential (17, 18). We showed that R5 variants predominate in both plasma 
as well as CSF samples, but that at least one CXCR4-using variant was present in plasma and/or 
CSF in ~43.8% of study-participants. Although we expected to detect CXCR4 usage by HIV-1C 
in some individuals in this study, considering that all had an AIDS defining condition, we 
observed a much higher frequency of CXCR4 usage than expected based on previous studies. It 
may be that the CPAs overestimated the predicted CXCR4 usage as described previously (74-77). 
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Coreceptor usage tests in vitro may be employed in future to corroborate our findings. It remains 
unclear, however, whether CXCR4-using variants are enriched in individuals depending on the 
co-infection they have, or that HIV-1C has evolved to use CXCR4 more over time. We also 
showed that 4/13 (30.8%) CSF samples harbored predicted CXCR4-using HIV-1C variants, 
indicating that different phenotypes besides R5 variants may circulate in the CNS in chronic to 
end-stage disease. The clinical importance of our findings may require further longitudinal 
evaluation considering that genetic intermixing between peripheral blood and the CNS may afford 
HIV-1 the ability to target cells of the CNS using CXCR4. 
 
Our study was limited to a small cohort of 16 participants with highly similar clinical 
characteristics. We did not have a control group of participants infected with HIV-1 but not 
presenting with CM. We generated a low number of sequence for one or both compartments of 
some participants, therefore we may have missed minority lineages that are specific to the 
peripheral blood or CNS compartment. Another limitation of the study which may have impacted 
the results of our study was the use of bulk PCR amplification and cloning together with SGA to 
generate sequences. SGA has been shown to provide a better measure of viral variants, especially 
minority ones, in a quasispecies compared to bulk PCR and cloning, as described previously (49). 
On the other hand, a different study showed that bulk PCR and cloning may adequately determine 
viral diversity as SGA does (78). 
Future longitudinal studies assessing differences of HIV-1 in blood and the CNS of individuals 
with and without CM will improve our understanding of the pathogenesis of HIV-1. Our results 
suggest that trafficking of HIV-1 variants between blood and the CNS is common, though the 
mode and the effect on HIV-1 neurotropism is not completely clear. We also established using 
CPAs that maraviroc use would not be suitable for approximately 44% of individuals with CM, 
suggesting an alternative mode of therapy must be optimized for them if standard regimens fail. 
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In Chapter 2, we determined the predicted coreceptor usage of HIV-1C variants in peripheral 
blood and the CNS of individuals with CM using CPAs. However, we did not conduct 
experiments to confirm the in vitro usage of CCR5 or CXCR4 by those variants. In Chapter 3, we 
present the in vitro ability of HIV-1C from plasma and the CSF of individuals with CM to infect 
cell lines expressing CCR5 or CXCR4. Additionally, the accuracy of three publicly available 
CPAs, and the determinants of CCR5 and CXCR4 usage are also presented.   
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3.1 Abstract 
The coreceptor usage of HIV-1 subtype C (HIV-1C) in patients with clinical end-stage infection 
and AIDS defining opportunistic infections such as cryptococcal meningitis (CM) is not well 
understood. To better understand HIV-1 subtype C pathogenesis and eligibility for maraviroc, a 
CCR5 receptor antagonist, in patients with advanced AIDS, we characterized the major 
coreceptor usage of HIV-1C in 10 and 12 plasma and cerebrospinal fluid samples, respectively, 
across 14 participants with CM. Eleven out of 12 (~91%) CSF samples harbored R5 viruses only, 
while the remaining sample had an R5X4 virus detected. In contrast, nine out of 10 (90%) plasma 
samples harbored R5 viruses, though three (30%) of those samples additionally had R5X4 and/or 
X4 viruses, while the remaining plasma sample had only X4 virus detected. Overall, four out of 
14 (~28.6%) participants harbored CXCR4-using viruses in plasma and/or cerebrospinal fluid. 
Our results suggest that HIV-1C envelope proteins in advanced AIDS use CCR5 and/or CXCR4 
frequently in peripheral blood but CCR5 almost exclusively in the central nervous system.  
 
Keywords: Cryptococcal meningitis, cerebrospinal fluid, HIV-1, plasma, maraviroc. 
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3.2 Introduction 
The envelope protein (Env) of the human immunodeficiency virus type 1 (HIV-1) engages the 
primary receptor, cell-surface CD4, and a chemokine receptor, normally CCR5 or CXCR4, which 
serves as a coreceptor for the virus to attach to the target cell and infect it (1-4). In primary HIV-
1 infection, CCR5 is the coreceptor used for target cell entry by almost all strains transmitted 
through the mucosal route (5, 6). In later stages of infection, the virus may switch coreceptor 
usage from CCR5 to CXCR4 and additional coreceptors (7), and the switch is associated with an 
accelerated rate of disease progression (8, 9). The mechanisms that underlie coreceptor switching 
by HIV-1 as disease progresses are not completely understood, and it has been reported that the 
extent of coreceptor switching is not consistent across different subtypes (10). Therefore, knowing 
the requirements and mechanisms of coreceptor switching is essential for understanding HIV 
disease progression.  
Recent studies of individuals in end-stage infection have yielded conflicting data on the 
prevalence of HIV-1C CXCR4 usage, though current evidence weighs towards higher frequency 
of CXCR4 usage than previously thought. In a small study of 20 participants, CXCR4-using HIV-
1C was detected in 30% of infected participants, whereas a larger cohort study of 148 participants 
showed CXCR4-using HIV-1C in approximately 15% of the participants. Both studies, however, 
highlighted that CXCR4 usage by HIV-1C may have increased in the general population over 
time, though better estimates of CXCR4 usage are required (11, 12). CXCR4 usage by HIV-1C 
has been observed in individuals presenting with various AIDS-defining illnesses (13-15), though 
it is unclear what the true prevalence is of CXCR4 usage by HIV-1C in larger cohorts with specific 
comorbidities or coinfections. Clearly, CXCR4 usage by HIV-1C is not insignificant, has 
relevance for disease pathogenesis and the applicability of CCR5 inhibitors which are now in 
clinical use.  
Because it is invasive to obtain a biopsy of the brain to study the properties of HIV-1 potentially 
resident there, cerebrospinal fluid (CSF) samples are often used as a surrogate (16). Although the 
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coreceptor usage by HIV-1 isolates in peripheral blood has been investigated thoroughly, much 
less is known about viral strains in the central nervous system (CNS). Studies have shown that it 
is primarily R5 T-cell tropic viruses that establish infection in the CNS (17), but viruses which 
use CXCR4 alone or in combination with CCR5 have also been observed in the CSF of 
individuals in the chronic stage of infection (18, 19).   
Coreceptor usage predictive algorithms (CPAs), which predict whether an isolate is R5 or 
CXCR4-using, have been designed to potentially replace in vitro characterizations of HIV-1 
coreceptor usage which are laborious, costly and time-consuming. There are three publicly 
available CPAs, Geno2pheno, PhenoSeq and WebPSSM subtype C sinsi (WebPSSM) that were 
developed using different training sets of HIV-1 Env V3 sequences and distinct algorithms for 
predicting coreceptor usage. All have been shown to be highly sensitive and specific for the 
detection of R5 and CXCR4-using viruses, respectively (20-25). However, at present, none of the 
CPAs are so accurate that they may replace in vitro coreceptor usage characterizations entirely. 
This is largely because determinants of coreceptor usage are not completely restricted to the V3 
loop, thus reducing reliability of CPAs (23, 26-29). Additionally, the majority of sequences used 
in the training sets for the development of CPAs were derived from viruses circulating in plasma 
and it is unclear whether the predictions are generalizable to viruses circulating in other 
anatomical compartments. An examination of the accuracy of CPAs with viruses derived from 
other anatomical compartments such as the central nervous system (CNS) has not been performed. 
One of the most common opportunistic infections in people with advanced HIV/AIDS infection 
in sub-Saharan Africa is cryptococcal meningitis (CM). Approximately 504,000 individuals die 
annually due to HIV-associated CM, making this coinfection a major public health problem in 
sub-Saharan Africa (30). Previously, we detected HIV-1C predicted to use CXCR4 in seven of 
16 patients who presented with CM with the aid of CPAs (Chapter 2). In that study, variants 
predicted to use CXCR4 were detected in plasma and cerebrospinal samples, though we did not 
conduct phenotypic tests to confirm that those variants were functional and indeed use CXCR4 
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in vitro. Here, we sought to confirm the coreceptor usage of those Envs using in vitro phenotypic 
assays, and to evaluate the accuracy of publicly available CPAs. Our results will contribute to our 
understanding of HIV-CM disease, the coreceptor tropism of HIV-1C in the CNS compartment, 
and the refinement of frequently used CPAs.  
 
3.3 Materials and methods 
3.3.1 Study participants   
The parent clinical study cohort including the participants selected for this study has been 
described previously (31). We initially had plasma and/or CSF samples from 16 participants 
shortlisted for analysis (Chapter 2), however, we only analyzed samples from 14 of those 
participants by the conclusion of this sub-study. Briefly, all the participants in this study were 
retrospectively selected based on CD4+ T-cell count, plasma and CSF viral load. At the time of 
analysis, all the participants were antiretroviral therapy-naïve, with a CD4+ T-cell count lower 
than 200 cells/µL, enumerated using the Becton Dickinson TruCount Technology (BD, Franklin 
lakes, NJ). They also had detectable HIV RNA in plasma and CSF according to the COBAS 
TaqMan HIV-1 test with a lower detection limit of 34 copies/mL (Hoffmann-La Roche, Basel, 
Switzerland), and experienced their first episode of CM. All but two participants, CM032 and 
CM117, had pleocytosis (white blood cell count of 5 cells/µL or more).  
 
3.3.2 RNA extraction and first-strand cDNA synthesis  
Total cell-free RNA from plasma and CSF was extracted using the QIAmp Viral RNA Mini kit 
(Qiagen, Dusseldorf, Germany) according to manufacturer’s instructions. The synthesis of single-
strand HIV cDNA from extracted RNA was performed using the SuperScript III (Invitrogen, 
Carlsbad, CA) according to manufacturer’s instructions. Briefly, extracted RNA was combined 
with primer OFM19 (5’-GCACTCAAGGCAAGCTTTATTGAGGCTTA-3’; HXB2 positions 
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9,604-9,632) and deoxynucleoside triphosphates, then the reaction mixture was heated to 65 °C 
for 5 minutes and  cooled to 4 °C immediately thereafter. The first-strand synthesis reaction 
incorporated the following reagents in the reaction mixture: 1X reverse transcriptase buffer with 
dithiothreitol, RNAseOut (Invitrogen) and SuperScript III. The complete reaction mixture was 
incubated at 50 °C for 60 minutes, 55 °C minutes for 60 °C, incubated at 70 °C for 15 minutes 
and cooled to 4 °C (32). To ensure that residual RNA was degraded, RNAse H (Invitrogen) was 
added to the complete reaction mixture. 
 
3.3.3 HIV-1 env gene amplification and cloning 
Full-length HIV-1 env genes were amplified by nested PCR, employing the single-genome 
amplification (SGA) or a bulk-genome amplification method. For the resolution of single-
genomes, cDNA was diluted serially, and multiple replicate PCR reactions of each dilution were 
performed using the Platinum Taq DNA Polymerase High Fidelity (Invitrogen) according to 
manufacturer’s instructions. Dilutions which yielded 30% or less positive amplifications had a 
high probability of containing single-genomes, according to Poisson’s distribution, as described 
previously (33). The first round PCR included the outer primers VIF1 and OFM19, while the 
second round PCR included the inner primers ENVA and ENVN (34, 35). The bulk-genome 
amplification method involved the purification of env genes without the dilution of cDNA. The 
first round of PCR included outer primers VIF1 and OFM19, and the second round of PCR 
included the inner primers Env-KpnI (5'-GTCTATTATGGGGTACCTGTGTGG-3'; HXB2 
positions 6,336-6,359) and Env-BamHI (5'-GCTAAGGATCCGCTCACTAATCG-3'; HXB2 
position 8,463-8,485) as described previously (34, 36).  
Cloning of the 2.1 kb KpnI-to-BamHI env fragment (positions 6,348 to 8,478: HXB2 numbering) 
has been described previously (36-38). Briefly, 2 µL of first round PCR products were added to 
a PCR reaction mixture including the following reagents: 1X Phusion HF buffer (New England 
Biolabs, Ipswich, MA), 10 mM of deoxynucleoside triphosphates, 10 µM of forward primer Env-
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KpnI, 10 µM of reverse primer Env-BamHI, 1 U of Phusion High-Fidelity DNA Polymerase 
(New England Biolabs), and nuclease free water for a final volume of 50 µL. Thermocycling 
conditions for the amplification of DNA were as follows: 1 cycle at 98 °C for 30 seconds; 35 
cycles of 98 °C for 10 seconds, 65 °C for 30 seconds, 72 °C for four minutes; 1 cycle at 72 °C for 
10 minutes and a hold at 4 °C. Amplicons were purified, digested using the Acc65I and BamHI 
restriction enzymes (Invitrogen), and ligated to pSVIII-Env vectors using the Rapid DNA 
Ligation Kit (Invitrogen). XL10-Gold Ultracompetent Cells (Agilent Technologies, Santa Clara, 
CA) were transformed with the recombinant pSVIII-Env vectors. 
 
3.3.4 Sequencing of env genes and subtyping  
Second round PCR products were sequenced to resolve the DNA sequences of env genes 
amplified by SGA. The env genes amplicons generated by bulk PCR were sequenced directly 
from pSVIII-Env expression plasmids following successful cloning. All env genes were 
sequenced bi-directionally using up to eight forward and reverse primers spanning the entire gene 
(39). The ABI 3130 genetic analyzer (Applied Biosystems, Waltham, MA) was used to resolve 
the env gene DNA sequences, and the contigs acquired from it were assembled and manually 
edited using Sequencher (Genecodes, Ann Arbor, MI). Sequence chromatograms which had 
overlapping peaks and duplicate sequences were discarded. To determine the subtype and confirm 
absence of inter-patient sequence contamination, the V1-V5 env gene regions of sequences from 
participants were first aligned together with those of sequences from subtypes A-K, group N and 
O obtained from the Los Alamos HIV sequence database (www.hiv.lanl.gov) using Clustal W. 
Then, the phylogenetic relatedness of the aligned sequences was inferred using the neighbor-
joining method in MEGA 7 (40): all positions containing gaps and missing data were stripped and 
the final tree was generated after 1,000 bootstrap replicates, as described previously (14). 
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3.3.5 Coreceptor usage prediction using three algorithms 
We used three coreceptor usage prediction algorithms (CPAs) to determine the predicted 
coreceptor usage of our env gene sequences. The publicly available CPAs, Geno2pheno with a 
5% false-positive rate (http://coreceptor.bioinf.mpi-inf.mpg.de/), WebPSSM subtype C sinsi 
(WebPSSM; https://indra.mullins.microbiol.washington.edu/webpssm) and PhenoSeq 
(www.burnet.edu.au/phenoseq) were used to determine the predicted coreceptor tropism of 
sequenced env genes (20-22). The CPAs use V3 loop sequences to predict whether viruses are 
CCR5-using only (R5), or CXCR4-using (R5X4 or X4). Where one CPA did not agree with the 
classification of the other two CPAs, the predicted tropism was determined based on two 
concordant CPAs.  
 
3.3.6 Identification of potential N-linked glycosylation sites 
Potential N-linked glycosylation sites (PNGS) in V3 loop sequences were counted using the 
publicly available program N-GlycoSite 
(https://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html). The program 
identifies N-X-[S or T] patterns in an amino acid sequence, where “X” can be any amino acid, 
except proline, and counts them as PNGS (41).  
 
3.3.7 Maintenance of mammalian cells 
293T cells were propagated in supplemented Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen) consisting of 10% fetal bovine serum, 1% GlutaMax (Invitrogen), and 1% penicillin-
streptomycin (Biochrom AG, Berlin, Germany). The human glioma cell lines, NP2-CD4 and 
U87-CD4 cells, transduced to express CCR5 or CXCR4 were propagated in supplemented 
DMEM with the addition of 1 µg/mL of puromycin and 300 µg/mL of G418 (Sigma-Aldrich, St. 
Louis, USA). All mammalian cells were incubated at 37 °C and 5% CO2.  
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3.3.8 Production of single-round replication luciferase reporter viruses 
To produce single-round replication luciferase reporter viruses (pseudoviruses), pSVIII-Env 
expression plasmids containing patient-derived or lab-strain env genes were cotransfected with 
plasmids pCMV∆P1∆envpA and pHIV-1Luc at a ratio of 1:1:3, respectively, into 0.6 X 106 293T 
cells using Lipofectamine 2000 (Invitrogen) or polyethylenimine, as described previously (37). 
At 48 hours post-transfection, supernatants were collected, passed through a 0.45 µm pore-filter 
and then stored at -80 °C.  
 
3.3.9 Coreceptor usage screen 
In order to determine the coreceptor used by Envs, we measured the ability of pseudoviruses to 
enter NP2-CD4 [42] or U87-CD4 cells expressing CCR5 or CXCR4 (43) as previously described 
(14). NP2-CD4 or U87-CD4 cells expressing CCR5 or CXCR4 were seeded at 1 X 104 cells per 
well in 96-well plates. Then, duplicated five-fold serial dilutions of pseudoviruses in 100 µL 
volumes were incubated with the cells and infections were allowed to proceed over a period over 
6-12 hours at 37 °C. Thereafter, fresh culture medium was supplied to the cells and incubation 
was continued for another 60 hours. Following that, the culture medium was discarded, cells were 
washed with phosphate-buffered saline (Invitrogen), and lysed using the Luciferase cell culture 
lysis reagent (Promega, Madison, WI). Pseudovirus entry was measured by assaying luciferase 
activity in cell lysates using the Luciferase Assay System (Promega), according to manufacturer’s 
instructions. Luminescence readings were acquired using the FLUOStar microplate reader (BMG 
Labtech, Champigny-sur-Marne, France) or the Modulus Microplate reader (Turner Biosystems, 
Sunnyvale, CA) and the mean relative units (RLU) were recorded. Pseudoviruses YU2 (R5 
tropic), JR-CSF (R5 tropic), 89.6 (R5X4 tropic) or HXB2 (X4 tropic) were included in the panel 
for comparison and assay quality control, whereas culture medium without pseudovirus was used 
as a negative control. Pseudovirus entry levels greater than 10-fold that of control levels and/or 
negative control pseudoviruses indicated the Env used the coreceptor exposed to it, while lower 
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than 10-fold control levels indicated the Env could not use the coreceptor. Pseudoviruses which 
used CCR5 only and CXCR4 only were classified as R5 and X4, respectively. Pseudoviruses 
which used both CCR5 and CXCR4 were classified as R5X4.  
 
3.3.10 Statistical analyses 
The unpaired, non-parametric t-test was performed using GraphPad Prism version 5 for Windows 
(GraphPad Software, San Diego, CA) unless otherwise stated. 
 
3.4 Results 
3.4.1 HIV-1 sequence and phylogenetic analyses 
A total of 14 antiretroviral naïve participants with CM were included in this study. The clinical 
characteristics of the participants are shown in Table 3-1. Across the 14 participants, we analyzed 
eight matched plasma and CSF samples. Additionally, two and four unmatched plasma and CSF 
samples, respectively, were also included in our analyses. Thus, we analyzed a total of 10 plasma 
and 12 CSF samples, respectively.  
 
From the 10 plasma and 12 CSF samples, 26 (median 2, range 1-7 per participant) and 40 (median 
2.5, range 1-16 per participant) env genes, respectively, were sequenced and cloned as described 
previously (35, 39). The predicted coreceptor usage of each virus was previously determined 
(Chapter 2). Notable, a combination of predicted R5 and CXCR4-using Envs, where present, from 
each compartment of each participant were selected for phenotyping in this sub-study. Based on 
phylogenetic analyses, all of the env genes analyzed in this study were confirmed to belong to 
subtype C, as they clustered together with reference subtype C sequences. Sequences obtained 
from the Los Alamos database representative of other subtypes clustered according to subtype, 
but separately from the study sequences. There was no evidence of inter-patient sequence 
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contamination as the sequences from each participant clustered together and did not mix with the 
sequences from other participants (Chapter 2). 
 
Table 3-1: Clinical characteristics and samples analyzed of the study participants. 
IDa Age Sexb 
CD4 
countc 
Pl 
VLd 
CSF 
VLe 
CSF 
WBCf 
Sampleg 
CM019 45 M 7 5.15 4.33 28 Pl and CSF 
CM021 30 F 134 4.34 4.34 40 CSF only 
CM029 33 F 121 5.22 5.99 424 CSF only 
CM032 34 F 5 4.94 2.52 0 Pl and CSF 
CM050 23 F 16 4.92 4.8 6 CSF only 
CM052 24 F 172 4.62 4.83 36 Pl and CSF 
CM054 23 M 7 5.2 4.2 14 Pl only 
CM070 25 M 11 5.04 4 18 Pl only 
CM089 27 M 114 5.67 5.85 154 Pl and CSF 
CM094 29 F 35 5.15 4.03 84 CSF only 
CM098 40 M 14 4.76 5.27 66 Pl and CSF 
CM108 27 M 20 5.16 5.02 28 Pl and CSF 
CM117 38 M 1 5.72 4.66 0 Pl and CSF 
CM132 34 M 53 4.58 4.43 38 Pl and CSF 
aThe identification number of the study participant. bThe sex of the study participant, where “M” 
refers to male and “F” refers to female. cThe CD4 count was recorded as cells/µL. d,eThe cell-free 
plasma (Pl) and CSF viral load (VL) was recorded as log10 HIV RNA copies/mL. fThe CSF white 
blood cell count (WBC) was recorded as cells/µL. gThe samples analyzed in this study. 
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3.4.2 Coreceptor usage of HIV-1C Envs  
The sequenced genes from the plasma and/or CSF samples of study participants coding for HIV-
1 gp160 were cloned into pSVIII-Env expression plasmids. In total, 66 single-round infection 
luciferase reporter viruses (pseudoviruses) pseudotyped with Envs from study participants were 
produced, and their ability to enter NP2-CD4 or U87-CD4 cells expressing CCR5 or CXCR4 was 
determined. There was good agreement of entry profiles of the HIV-1B pseudovirus infection 
controls between NP2-CD4 and U87-CD4 cells, and we confirmed that pseudoviruses YU2 and 
JR-CSF are R5, while HXB2 and NL4.3 are X4, and 89.6 is dual-tropic. Overall, we identified a 
total of 50 R5, seven X4, four R5X4, and five Envs which did not register usage of CCR5 or 
CXCR4. The in vitro entry profiles of the infection controls and pseudoviruses pseudotyped with 
participant-derived HIV-1C Envs evaluated in our study are shown in  
 
Figure 3.1: The usage of CCR5 and CXCR4 of HIV-1 subtype C Envs in individuals with 
cryptococcal meningitis. 
, and summarized in Table 3-2.  
Eleven out of 12 (~91.7%) CSF samples harbored R5 viruses exclusively, while the remaining 
CSF sample (~8.3%) from participant CM019 had an R5X4 virus detected in the CSF. Nine out 
of 10 (90%) plasma samples possessed R5 viruses, though three (30%) of those samples (from 
CM019, CM098 and CM108) also contained CXCR4-using viruses. Specifically, the plasma 
sample from participant CM019 had R5, R5X4 and X4 viruses; plasma of CM098 had R5 and X4 
Envs, and plasma of CM108 had R5 and R5X4 viruses. The only virus tested for participant 
CM070 was plasma-derived and X4-tropic. Coreceptor tropism of viruses overlapped between 
the matched plasma and CSF-derived viruses of all eight (100%) participants. Notably for 
participants CM098 and CM108, CXCR4-using Envs were not detected in the CNS compartment, 
suggesting that for these participants there may have been partial compartmentalization of 
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coreceptor usage, with CXCR4-using variants detected in plasma but not in CSF. Overall, we 
detected CXCR4-using variants in four out of 14 (~28.6%) participants. These results suggest that 
HIV-1C in peripheral blood and CNS compartments prefers to use CCR5 predominantly over 
CXCR4 in individuals with end-stage HIV and CM. Additionally, in individuals with CXCR4-
using variants, CXCR4 may be used exclusively or in combination with CCR5.  
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Figure 3.1 (A) 
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Figure 3.1 (B) 
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Figure 3.1 (B) continued 
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Figure 3.1 (B) continued 
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Figure 3.1 (B) continued 
 
 
 
Figure 3.1: The usage of CCR5 and CXCR4 of HIV-1 subtype C Envs in individuals with 
cryptococcal meningitis. 
Single-round infection luciferase reporter viruses (pseudoviruses) pseudotyped with plasma or 
cerebrospinal fluid-derived HIV-1 subtype C Env (listed on the x-axis) were used to infect NP2-
CD4 cells (A) expressing CCR5 (top) and CXCR4 (bottom), or U87-CD4 cells (B) expressing 
CCR5 (top) and CXCR4 (bottom), as described in Materials and methods. Pseudoviruses with a 
star symbol beside their name indicate they were pseudotyped with an Env derived from the CSF, 
whereas pseudoviruses without a star beside them indicate their Env was derived from plasma. 
Luciferase activity in cell lysates, measured as relative light units (RLU), was used as a measure 
of pseudovirus entry. Entry of each pseudovirus at different dilutions (1:1, 1:5, 1:25 and 1:125) 
was tested in duplicate and the mean values were recorded. Pseudoviruses baring HIV-1B Envs 
(HXB2, JR-CSF, YU2 and 89.6) were included in the assay as infection controls, as well as 
culture medium without pseudovirus (negative control). Pseudoviruses recording levels of entry 
that were greater than 10-fold that of the infection and negative control (black line cutoff) were 
able to use the coreceptor for entry. Pseudoviruses using CCR5, CXCR4 or both CCR5 and 
CXCR4 were classified as R5, X4 or R5X4, respectively. 
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Table 3-2: The predicted and in vitro coreceptor usage of HIV-1C Envs in individuals with CM. 
IDa Clonesb Compartmentc G2Pd PhenoSeqe PSSM-Cf Consensusg In vitro tropismh 
CM019 
CM019C.B CSF CXCR4-using CXCR4-using CXCR4-using CXCR4-using R5X4 
CM019P.3 
Plasma 
CXCR4-using CXCR4-using CXCR4-using CXCR4-using X4 
CM019P.B.3 CXCR4-using CXCR4-using CXCR4-using CXCR4-using R5X4 
CM019P.B.4 CXCR4-using CXCR4-using CXCR4-using CXCR4-using X4 
CM019P.B.5 CXCR4-using CXCR4-using CXCR4-using CXCR4-using X4 
CM019P.B.6 CXCR4-using CXCR4-using CXCR4-using CXCR4-using X4 
CM019P.H.1 R5 CXCR4-using R5 R5 R5 
CM019P.I.2 R5 R5 R5 R5 R5 
CM021 CM021C.7.3 CSF R5 R5 R5 R5 R5 
CM029 
CM029C.B.3 
CSF 
R5 R5 R5 R5 R5 
CM029C.D.2 R5 R5 R5 R5 R5 
CM029C.E.2 R5 R5 R5 R5 R5 
CM029C.G.2 R5 R5 R5 R5 R5 
CM032 CM032C.6.4 CSF CXCR4-using CXCR4-using CXCR4-using CXCR4-using R5 
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IDa Clonesb Compartmentc G2Pd PhenoSeqe PSSM-Cf Consensusg In vitro tropismh 
CM032P.6.3 Plasma R5 CXCR4-using CXCR4-using CXCR4-using R5 
CM050 
CM050C_SGA02 
CSF 
R5 CXCR4-using CXCR4-using CXCR4-using R5 
CM050C_SGA04.2 R5 CXCR4-using CXCR4-using CXCR4-using R5 
CM050C_SGA14 R5 CXCR4-using CXCR4-using CXCR4-using R5 
CM052 
CM052C.1 CSF R5 R5 R5 R5 R5 
CM052P.2.1 
Plasma 
R5 R5 R5 R5 R5 
CM052P.2.2 R5 R5 R5 R5 R5 
CM052P.4.3 R5 R5 R5 R5 R5 
CM054 CM054P.11.6 Plasma R5 R5 R5 R5 R5 
CM070 CM070P.1 Plasma CXCR4-using CXCR4-using CXCR4-using CXCR4-using X4 
CM089 
CM089C_SGA13 
CSF 
R5 R5 R5 R5 R5 
CM089C_SGA16 R5 R5 R5 R5 R5 
CM089P_SGA06 plasma R5 R5 R5 R5 R5 
CM094 
CM094C.11.2 
CSF 
R5 R5 R5 R5 R5 
CM094C.14.2 R5 R5 R5 R5 R5 
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IDa Clonesb Compartmentc G2Pd PhenoSeqe PSSM-Cf Consensusg In vitro tropismh 
CM094C.6.2 R5 R5 R5 R5 R5 
CM098 
CM098C.1 
CSF 
R5 CXCR4-using R5 R5 - 
CM098C.C.2 CXCR4-using CXCR4-using CXCR4-using CXCR4-using - 
CM098C.C.3 R5 CXCR4-using R5 R5 R5 
CM098C.F.1 R5 R5 R5 R5 R5 
CM098C.F.2 R5 CXCR4-using CXCR4-using CXCR4-using R5 
CM098C.F.3 R5 CXCR4-using R5 R5 R5 
CM098C.F.5 R5 CXCR4-using CXCR4-using CXCR4-using R5 
CM098C.G.1 R5 CXCR4-using R5 R5 R5 
CM098C.G.2 R5 CXCR4-using R5 R5 R5 
CM098C.G.4 R5 CXCR4-using R5 R5 R5 
CM098C.G.5 R5 CXCR4-using R5 R5 R5 
CM098C.H.1 R5 R5 R5 R5 R5 
CM098C.H.5 R5 R5 R5 R5 R5 
CM098C.I.1 R5 R5 R5 R5 R5 
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IDa Clonesb Compartmentc G2Pd PhenoSeqe PSSM-Cf Consensusg In vitro tropismh 
CM098C.I.3 R5 R5 R5 R5 R5 
CM098C.J.4 R5 R5 R5 R5 R5 
CM098P.A.1 
Plasma 
CXCR4-using CXCR4-using CXCR4-using CXCR4-using X4 
CM098P.A.2 CXCR4-using CXCR4-using CXCR4-using CXCR4-using X4 
CM098P.B.1 R5 CXCR4-using R5 R5 R5 
CM098P.G.1 R5 R5 R5 R5 R5 
CM108 
CM108C.7.8 
CSF 
R5 R5 R5 R5 R5 
CM108C.8.9 R5 R5 R5 R5 R5 
CM108C.B.3 R5 R5 R5 R5 R5 
CM108C.D.8 R5 R5 R5 R5 R5 
CM108P.1 
Plasma 
CXCR4-using CXCR4-using CXCR4-using CXCR4-using R5X4 
CM108P.4 CXCR4-using CXCR4-using CXCR4-using CXCR4-using R5X4 
CM108P.D.5 R5 CXCR4-using CXCR4-using CXCR4-using R5 
CM117 
CM117C.A 
CSF 
R5 R5 R5 R5 R5 
CM117C.H.1 R5 R5 R5 R5 - 
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IDa Clonesb Compartmentc G2Pd PhenoSeqe PSSM-Cf Consensusg In vitro tropismh 
CM117C.I.1 R5 R5 R5 R5 R5 
CM117P.F.2 
Plasma 
R5 R5 R5 R5 - 
CM117P.H.1 R5 R5 R5 R5 - 
CM117P.I.1 R5 R5 R5 R5 R5 
CM117P.O.1 R5 R5 R5 R5 R5 
CM132 
CM132C.1 CSF R5 R5 R5 R5 R5 
CM132P_SGA02 plasma R5 R5 R5 R5 R5 
aThe patient identification number. bThe name of the unique pseudotyped Env. cThe compartment which is represented by the Env-pseudotyped 
pseudovirus. d,e,fThe predicted coreceptor tropism of the pseudovirus according to Geno2pheno (G2P), PhenoSeq and WebPSSM subtype C sinsi (PSSM-
C), respectively. gThe consensus predicted coreceptor tropism of the pseudovirus based on the agreement of any two CPAs. hThe coreceptor tropism of 
the Env based on its ability to mediate entry into NP2-CD4/U87-CD4 cells expressing CCR5 or CXCR4. Dashes indicate envelopes unable to mediate 
entry using CCR5 and CXCR4. 
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3.4.3 The accuracy of publicly available coreceptor usage prediction algorithms 
The predictions of coreceptor usage for the Envs in this study are summarized in Table 3-2. The 
three CPAs agreed with each other generally, sharing the same prediction on 50 out of 66 
(~75.8%) occasions. We evaluated the accuracy of the individual CPAs to identify which was the 
most reliable. The three CPAs were 100% accurate when predicting CXCR4 usage, but had 
predicted multiple false positives for CXCR4 use. Geno2pheno was the most accurate, accurately 
predicting 49 out of 50 (98%) R5 viruses. PSSM-C was less accurate, predicting 42 out of 50 
(84%) R5 viruses accurately. PhenoSeq was the least accurate, predicting 34 out of 50 (68%) R5 
viruses accurately. Next, we evaluated whether or not using the CPAs in combination would 
provide better accuracy, so we determined the overall predicted coreceptor usage of each virus 
based on the agreement of at least two CPAs. For 15 out of 61 (~24.6%) viruses which used CCR5 
and/or CXCR4, however, one CPA did not agree with the prediction of the other two. Overall, 
using three CPAs provided an expected 100% accuracy when predicting CXCR4-using viruses. 
Forty-two out of 50 (84%) R5 viruses were predicted accurately using the CPAs, suggesting that 
using a combination of CPAs to determine coreceptor usage may not be superior to using 
Geno2pheno or WebPSSM alone, but it is more accurate than using PhenoSeq alone. Also, three 
participants (CM032, CM050 and CM098) with CXCR4-using variants predicted to circulate in 
the CSF had, in fact, R5 viruses in the CSF only. This shows that CPAs may overestimate the 
presence of CXCR4-using viruses in some samples. 
 
3.4.4 V3 properties of R5 and CXCR4-using viruses 
Although a total of 66 unique env genes were sequenced, cloned and used to prepare 
pseudoviruses, there were only 35 unique V3 loop sequences between them. Combining the 
results of coreceptor usage determinations in vitro and sequencing information, we were able to 
identify well-known determinants of CXCR4 usage based on Env V3 loop properties (Figure 3.2). 
Most of the R5 viruses in this study had a Env V3 crown motif consisting of a GPGQ sequence, 
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except for three viruses, predicted to use CXCR4, from participant CM050 and one from CM108 
(Env CM108P.D.5 had a GPGH, and the Envs from CM050 had a GPGK motif), whereas all of 
the CXCR4-using Envs had a positively charged residue at position 16 and/or 18 of the V3 within 
the crown motif.  
Statistically significantly length differences between R5 and some CXCR4-using Env V3s were 
not previously identified (Chapter 2). However, the V3 length of some CXCR4-using viruses 
from participants CM019, CM070P and CM098 was longer (37 amino acids) than the majority of 
viruses in the study due to a two-amino acid insertion (isoleucine-glycine or leucine-glycine) 
upstream of the crown motif. All of the R5 viruses, on the other hand, had a V3 that was 35 amino 
acids long. A longer V3 loop was not compulsory for usage of CXCR4, however, as V3 sequences 
of CXCR4-using viruses from CM108 were 35 amino acids long.  
Only one PNGS was identified in the V3 of all R5 viruses at position 6, whereas multiple CXCR4-
using viruses from participant CM019 lacked a V3 PNGS. CXCR4-using viruses from CM070, 
CM098 and CM108 maintained a PNGS at position 6 like R5 viruses suggesting that the absence 
of a PNGS alone does not account entirely for usage of CXCR4.  
CXCR4-using viruses in this study possessed a significantly higher (p<0.0001) net charge of the 
Env V3 (median +5; range 5-7) than R5 viruses (median +4; range 2-6) (data not shown), and this 
was consistent with observations in Chapter 2. Although the CXCR4-using viruses of participants 
CM070, CM098 and CM108 had charged residues at position 11 and/or 25 of the V3 which has 
been previously been associated with CXCR4 usage, the R5 viruses from participant CM032 also 
had charged residues at position 25 of the V3. 
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Figure 3.2: An amino acid alignment of unique HIV-1C Env V3 sequences showing the 
determinants of CXCR4 usage. 
A reference South African HIV-1C Env V3 sequence (Ref.C.ZA) was aligned with HIV-1C Env 
V3 sequences derived from the plasma and/or CSF of study participants with cryptococcal 
meningitis using MUSCLE. The number in the round brackets next to the sequence name 
indicates the total number of Envs in the study which shared the same V3 sequence; the absence 
of a bracketed number indicates that only that Env had the sequence. A star symbol indicates an 
Env that was in the CSF, and the absence of a star symbol indicates the Env was from plasma. A 
dagger symbol indicates an X4 Env, a double-dagger symbol indicates an R5X4 Env and the 
absence of a dagger and double-dagger indicates the Env was R5. A dash between square brackets 
indicates an Env which did not utilize CCR5 or CXCR4 for entry. Two-amino acid insertions are 
indicated within green boxes, a red underlining shows a crown motif sequence different to GPGQ. 
Black squares show V3 sequences without a PNGS at position 6, and blue squares show V3s with 
a positively charged residue at position 11 and/or 25. The length of the V3 is shown on the right-
hand side of the protein sequence. 
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3.4.5 Some Envs may be functionally defective or do not use CCR5 or CXCR4 
We identified five Envs (two CSF-derived Envs from participant CM098; one CSF-derived, and 
two plasma-derived Envs from participant CM117) which were unable to use CCR5 or CXCR4 
for entry. This suggests that they were functionally defective or used alternative coreceptors. We 
noted, however, that parts of the V3 and other regions of the Envs may be responsible for these 
observations. Env CM098C.C.2 (from participant CM098) had a 7 amino acid deletion within the 
V3, commencing at position 18 and ending at position 24, which may have affected its usage of 
CCR5 and CXCR4. Env CM098C.1 (from participant CM098), CM117P.F.2 and CM117P.H.1 
(from participant CM117) shared the entire V3 loop sequence with other R5 Envs, suggesting that 
the difference of coreceptor usage or functional defect was not in the V3 but elsewhere in Env. 
We were unable to identify a possible reason why CM117C.H.1 was unable to use CCR5 or 
CXCR4.  
 
3.4.6 Rare mutation at position 14 of the V3 loop of HIV-1C Envs from one participant 
Position 14 of the V3 loop (immediately upstream of the crown motif) of all Envs sequenced in 
this study was occupied by a conserved isoleucine residue, except for Envs from participant 
CM108. Plasma as well as CSF-derived Envs of participant CM108 had a phenylalanine residue 
occupying position 14 of the V3 in place of an isoleucine. The occurrence of this rare residue at 
that position did not, however, make the pseudoviruses defective as all the Envs with the rare 
residue were able to use CCR5 and/or CXCR4 for entry.  
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3.5 Discussion 
Overall, we showed that antiretroviral naïve HIV-infected individuals experiencing CM harbor 
HIV-1C which predominantly uses CCR5 for entry in peripheral blood and the CNS 
compartment. We were also able to show that the CNS compartment predominantly consists of 
R5 viruses but not X4 viruses, while R5, R5X4 and X4 viruses are found in peripheral blood. Our 
appraisal of CPAs revealed that Geno2pheno, PhenoSeq and WebPSSM generally provide the 
same prediction of HIV-1C coreceptor usage. Though all the three CPAs were 100% accurate 
with predicting CXCR4-usage, Geno2pheno was better with predicting R5 virus accurately 
compared with the other two CPAs. With the combination of phenotypic and sequence 
information, we were able to show that R5 viruses have Env V3 properties which are different to 
CXCR4-using viruses.  
Many studies regarding the coreceptor tropism of HIV-1C were relevant to the peripheral blood 
compartment (11, 13-15, 44-51), whereas few have characterized viruses from the CNS 
compartment (18, 52, 53). Our study was uniquely designed to characterize the major HIV-1C 
coreceptor tropism in the peripheral blood and CNS compartment of individuals with end-stage 
HIV disease and CM.  
 
Our results are consistent with previous observations that for South African HIV-1C, at advanced 
stages of disease, the infection is still dominated principally by R5 tropic viruses (11, 13, 54). We 
also show that HIV-1C is capable of using CCR5 or CXCR4 exclusively, and CCR5 in 
combination with CXCR4 in end-stage, as described previously (13, 46). More specifically, we 
identified that R5 viruses predominated in 90% of plasma samples, but noted that R5X4 and X4 
viruses were also detectable in 20% and 30% of samples, respectively. In contrast, approximately 
91% of CSF samples possessed R5 viruses only, another ~8.3% of samples harbored R5X4 
viruses and no sample had X4 viruses. Our results suggest that the usage of CCR5 by HIV-1 is 
required for entry in the CNS, as previously described (55-58). Additionally, we showed that 
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HIV-1C R5 viruses generally occupy the CSF, that R5X4 viruses are rare and X4 viruses are 
absent in that compartment, as described previously (18). 
 
All eight participants with Envs tested from both plasma and CSF compartments displayed 
coreceptor tropism overlap between the two compartments: at least one Env from plasma had the 
same tropism as at least one Env in the CSF. R5 tropism overlapped between compartments in 
seven participants, though R5X4 tropism overlap was also detected in one participant. For two 
participants with inter-compartment overlap of R5 viruses, CM098 and CM108, we additionally 
identified CXCR4-using viruses in plasma but not the CSF suggesting there may be partial 
compartmentalization of tropism. Previous studies shared similar results to ours, identifying that 
discordance of coreceptor usage may arise between plasma and CSF isolates (18, 19).  
A study by Sturdevant et al (2012) highlighted that the usage of CCR5 by HIV-1C Envs in plasma 
and CSF may be different, and that macrophage tropic viruses may arise specifically in the CNS 
compartment (17). We did not determine the efficiency of CCR5 usage of viruses in our study 
and may have missed tissue tropism differences of viruses between plasma and CSF.  
Because the majority of our sequences were obtained using bulk PCR, cloning and Sanger 
sequencing, we may have lost the opportunity to detect minor variants or coreceptor usage 
combinations in both compartments. We also collected a small number of viruses per participant 
which may have limited our ability to resolve phenotypic compartmental differences of HIV-1C 
Envs. Previously, other studies were able to accurately determine the composition of the 
quasispecies in plasma and CSF using repeated SGA which allows for the detection of minor 
variants (17, 53, 59, 60). However, for even greater sensitivity in detecting variants that are not 
detected in a quasispecies by bulk PCR techniques, deep sequencing approaches may be 
considered in future (61).  
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Our small collection of sequences allowed us to determine the predictive accuracy of publicly 
available CPAs. Geno2pheno, PhenoSeq and WebPSSM provided high accuracy when predicting 
R5 tropism or CXCR4 usage as previously observed (20-22, 24, 25). In our study, Geno2pheno 
was the best at predicting R5 tropism accurately, followed by WebPSSM and then PhenoSeq. 
This suggests that Geno2pheno is applicable and best for subtype C sequences despite that it was 
designed using subtype B sequences predominantly (24, 25, 62). All of the CPAs showed 
equivalent, high accuracy in their predictions of CXCR4 usage. We did note, however, that CPAs 
may incorrectly call viruses as CXCR4-using which may lead to an overestimation of the 
prevalence of CXCR4 usage, as described previously (63-65). The CPAs require refinement if 
they are to be used in the clinic as replacements of in vitro phenotypic assays, especially to 
eliminate the identification of false positive CXCR4 usage. The identification of false positive 
CXCR4-using variants would incorrectly disqualify patients from accessing therapeutic CCR5 
antagonists. Our results contribute to the refinement of current and future CPAs.  
 
Through the analysis of V3 loop sequences, we were able to identify determinants of CCR5 and 
CXCR4 usage. CXCR4-using viruses had at least two of the following features of the Env V3 
loop: one or two positively charged residues in the crown motif, a two-amino acid insertion 
upstream of the crown motif, a positively charged residue at position 11 and/or 25, an absence of 
a PNGS at position 6, or a net charge of +5 and above. The determinants of CXCR4 usage which 
we observed were consistent with those observed by others regarding HIV-1C Env (13, 14, 46, 
66, 67). Features of the V3 loop unique to R5 viruses such as low net charge, shorter length, and 
the GPGQ crown motif were also identified as described previously (54, 68).  
 
Many studies have shown CXCR4 usage by HIV-1 in plasma, but few have shown CNS-derived 
Envs using CXCR4 in vitro (18, 52, 69, 70). We confirmed that CXCR4 usage is not always 
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limited to the viruses circulating in plasma, as we identified one participant with a R5X4 CSF-
derived virus. Unexpectedly, we identified three participants with plasma viruses which used 
CXCR4 exclusively, suggesting that HIV-1C may persist without using CCR5 in end-stage 
disease. We did not, however, confirm the usage of CCR5 or CXCR4 by Envs in this study using 
coreceptor antagonists such as Maraviroc or AMD3100. Future studies may also explore site-
directed mutagenesis as a tool for revealing novel determinants of CXCR4 usage. 
 
The residue at position 14 of the envelope V3 loop (position 309 HXB2 numbering), immediately 
upstream of the crown motif, is highly conserved, displaying an isoleucine in 99% of HIV-1C 
sequences found in the Los Alamos sequence database 
(https://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html). When an isoleucine does not 
occupy that position, a leucine residue is preferred by HIV-1C albeit in less than 1% of the 
sequences in the database. Because the V3 crown motif consists of antiparallel β-strands forming 
β-hairpins, changes at position 14 alter the conformation of the V3, and may affect envelope 
recognition by antibodies by masking the CD4 site (71). Although the I309L mutation does not 
alter virus replication and spread observably, it does enhance the ability of HIV-1C to infect 
monocyte-derived macrophages and a cell line expressing low levels of CD4, suggesting the 
mutation affects exposure of the CD4 binding site and usage of CD4 for entry (72). A recent study 
showed that a functional R5 HIV-1C may bear an envelope M309 residue (46). In our study, we 
identified multiple functional plasma and CSF-derived viruses from one participant bearing an 
unusual F309 in the V3 loop. Furthermore, F309 was not specific to CCR5 or CXCR4-using 
viruses, as R5 and R5X4 viruses had the residue. We did not, however, evaluate the functional 
importance of the residue through site-directed mutagenesis. The biological impact of F309 may 
be evaluated by substituting it with isoleucine and testing the ability of those viruses to enter CD4+ 
T-cells and monocyte-derived macrophages. If F309 confers a biological advantage or 
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disadvantage to HIV-1C, it may influence future vaccine design strategies involving antibodies 
which target Env.  
 
All the participants in our cross-sectional study were classified as having AIDS, because they 
generally had high viral load counts, a CD4 count lower than 200 cells/µL and CM. We did not 
include other control groups or longitudinal samples in our study to better understand the impact 
of HIV-1C in HIV-CM co-infection. A control group of antiretroviral naïve HIV-1C infected 
individuals, with low CD4 count but without co-infection, would have been advantageous for 
understanding coreceptor usage of HIV-1C in advanced stages of HIV-1C infection. A second 
control group of participants with healthy CD4 counts would have improved our understanding 
of HIV coreceptor tropism before accelerated disease progression commences. Nevertheless, our 
study provided valuable insight into the coreceptor usage of HIV-1C in the peripheral blood and 
CNS compartments of patients experiencing CM. These data also highlight that the use of 
therapeutic CCR5 antagonists may be beneficial for targeting HIV-1C in most individuals with 
CM. However, due to the propensity of HIV-1C to use CXCR4 in end-stage disease, phenotypic 
assays to determine coreceptor usage of viruses ought to be conducted before CCR5 antagonists 
are administered.  
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In the background and literature review presented in Chapter 1, we indicated that HIV-1 has the 
capacity to expand its usage of  major coreceptors over the course of infection, and that this is 
associated with the ability of the virus to use alternative coreceptors. Furthermore, while HIV-1C 
in peripheral blood has been shown to use alternative coreceptors for entry, though it is unclear 
whether viruses circulating the CSF are also capable of using alternative coreceptors.  In Chapter 
3, we showed that HIV-1C variants circulating in the blood and the CNS have the ability to use 
CCR5 alone, CXCR4 alone, or CCR5 and CXCR4. However, we did not evaluate whether or not 
those variants are capable of entering cell lines using an alternative coreceptor. In Chapter 4, we 
present the ability of HIV-1C from plasma and CSF samples to enter a cell line which expresses 
CCR3, an alternative coreceptor.  
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4.1 Abstract  
Limited information is available regarding the coreceptor usage of HIV-1 subtype C in the central 
nervous system. Some evidence indicates that uncultured HIV-1 envelope glycoproteins (Envs) 
may efficiently use CCR3 as an additional coreceptor for entry. Here, 46 Env proteins, from the 
plasma and/or cerebrospinal fluid (CSF) of 14 antiretroviral therapy naïve individuals with end-
stage HIV-1 disease and cryptococcal meningitis (CM) were evaluated for their ability to use 
CCR3. Eight of 14 participants had matched plasma and CSF samples analyzed. Four of the eight 
participants with matched plasma and CSF samples harbored CCR3-using HIV-1C in both 
compartments, whereas the other four had no evidence of CCR3 usage. Two other participants 
with only plasma samples analyzed did not possess any CCR3-using viruses, whereas one of four 
other participants with only CSF samples analyzed harbored CCR3-using viruses.  Overall, a total 
of five (~35.8%) participants harbored CCR3-using viruses in plasma and/or CSF samples. These 
results show that HIV-1 subtype C in individuals with end-stage disease and CM commonly uses 
CCR3 as an alternative coreceptor in peripheral blood and the central nervous system.  
 
Keywords: CCR3, Cryptococcal meningitis, cerebrospinal fluid, plasma, envelope, HIV-1, 
plasma. 
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4.2 Introduction 
In addition to the primary CD4 receptor, transmitted human immunodeficiency virus type 1 (HIV-
1) envelope proteins (Envs) typically use the CCR5 chemokine receptor for cell entry (1, 2). 
However, in chronic to end-stage HIV disease, viruses with the ability to use other coreceptors, 
particularly CXCR4 arise and this is associated with an accelerated rate of the development of 
acquired immune deficiency syndrome (AIDS) (3, 4). The change of biological phenotype from 
non-syncytium-inducing (later associated with CCR5 usage) to syncytium-inducing (associated 
with CCR5 and CXCR4 usage or CXCR4 usage alone) in chronic stage disease has been observed 
in 50% of patients harboring HIV-1 subtype B (HIV-1B) (5). In contrast, some studies observed 
the usage of CXCR4 by HIV-1 subtype C (HIV-1C) to be infrequent or absent, indicating that 
HIV-1C disease progression is not dependent on a switch of coreceptors (6-12). However, other 
studies have suggested that CXCR4 usage by HIV-1C is not uncommon in individuals with 
advanced or end-stage HIV disease and may occur in approximately 15-30% of individuals (13-
15).  
The implications of alternative coreceptor usage (receptor other than CCR5 and CXCR4) by HIV-
1 for disease progression and neurotropism are less clear, though usage of alternative coreceptors 
may highlight the enhanced pathogenicity of HIV-1. Previous reports suggested that CCR3, which 
is expressed highly on microglia of the central nervous system (CNS), may act as a coreceptor for 
the infection of microglia by HIV-1 (16-18). Later studies, however, showed that CCR3-using 
HIV-1 variants are common in chronic or end-stage disease, and are not restricted to the CNS 
compartment (19, 20).  
HIV-1 subtype C (HIV-1C) Envs were shown previously to be capable of using alternative 
coreceptors such as CCR3, CCR8, CXCR6, BOB/GPR15 or FPRL1 for entry, but those Envs 
were derived largely from peripheral blood (21-26). One study of plasma and cerebrospinal 
(CSF)-derived isolates in individuals with chronic stage HIV-1 disease showed that alternative 
coreceptor usage discordance between peripheral blood and CNS was common, that HIV-1C may 
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use CXCR6 (another alternative coreceptor) in the CNS but not peripheral blood, while the usage 
of other alternative coreceptors was less pronounced. Additionally, one individual was shown to 
possess HIV-1C Env variants capable of using CCR3 in a CSF sample but not the matched 
plasma. The study highlighted that conclusions relating to HIV-1 Env phenotypes in peripheral 
blood may not be representative of the CNS compartment (24).  
It has been suggested that in vitro co-culture of peripheral blood mononuclear cells (PBMCs) 
before cloning Env variants for the study of HIV-1 entry phenotypes may under-represent the 
population of CCR3-using variants, and that direct cloning of HIV-1 variants may provide a more 
accurate representation of the viral population (27). Here, our aim was to determine the frequency 
of CCR3 usage by cell-free HIV-1C derived from peripheral blood and/or CSF of in individuals 
with end-stage HIV-1C disease and presenting with cryptococcal meningitis (CM), an AIDS-
defining illness. 
 
4.3 Methods and materials 
4.3.1 Study participants 
The 14 randomly selected combination antiretroviral therapy (cART)-naïve participants in this 
study were part of a longitudinal prospective cohort study of CM described previously (28). All 
participants were CSF positive for cryptococcal antigen (CrAg) or Indian ink test, had a CD4+ T-
cell count lower than 200 cells/µL according to Becton Dickinson TruCount Technology (BD, 
Franklin lakes, NJ), and detectable HIV-1 RNA in plasma and CSF based on the COBAS TaqMan 
HIV-1 test (Hoffmann-La Roche, Basel, Switzerland) with a lower detection limit of 34 HIV-1 
RNA copies/mL. Of note, all but two participants had pleocytosis, a CSF white blood cell (WBC) 
count of five or more cells per microlitre, suggesting ongoing inflammation in the CNS.  
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4.3.2 Synthesis of cDNA, the amplification and sequencing of HIV-1 env genes 
Cell-free RNA was extracted from the plasma and CSF of all the participants using the QIAmp 
Viral RNA Mini kit according to the manufacturer’s instructions (Qiagen, Valencia, CA).  Single-
strand HIV cDNA synthesis was performed using the SuperScript III reverse transcriptase 
(Invitrogen Life Technologies, Carlsbad, CA) as described previously (29). Full-length HIV-1 
env genes were amplified according to the single-genome amplification (SGA) or the standard 
(bulk) amplification method as described elsewhere (29), and sequenced bi-directionally using up 
to eight forward and reverse primers using the Sanger method (Chapter 2) (30, 31).  
 
4.3.3 Identification of HIV-1 env gene subtype 
The subtype of the env genes was identified by constructing a neighbor-joining phylogenetic tree 
incorporating the V1-V5 env gene fragments of participant-derived and reference HIV-1 subtype 
sequences, available on the Los Alamos National Laboratory HIV database 
(https://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html). Sequences alignments and 
phylogenetic inferences were performed in MEGA 7 (32), as described previously (Chapter 2) 
(12). 
 
4.3.4 Cloning of HIV-1 env genes and the production of pseudoviruses  
The 2.1 kb env gene fragments, corresponding to nucleotides 6,348 to 8,478 according to HXB2 
numbering were amplified, purified, and cloned into the pSVIII-Env expression vector (19, 33). 
Single-round infection luciferase reporter viruses (pseudoviruses) with participant-derived Envs 
were produced in 0.6 X 106 293T cells, by co-transfecting 0.8 µg of recombinant pSVIII-Env 
vectors with 0.8 µg  of pCMV∆P1∆envpA and 2.4 µg of pHIV-1Luc using polyethylenimine as 
previously described (33). The co-transfected 293T cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM; Invitrogen Life Technologies) containing 10% fetal bovine serum, 1% 
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of 1X Glutamax (Invitrogen Life Technologies) and 1% penicillin-streptomycin (Biochrom AG, 
Berlin, Germany) at 37 °C and 5% CO2. After a 48 hour period, the culture supernatants 
containing pseudoviruses were collected, passed through a 0.45 µm filter and stored at -80 °C.  
 
4.3.5 Major coreceptor usage of HIV-1C 
The major coreceptor usage of HIV-1C Envs in this study was determined previously (Chapter 
3). Envs which entered only NP2-CD4 or U87-CD4 cells expressing CCR5 were classified as R5, 
those entering using CXCR4 only were classified as X4, and those entering the cells using CCR5 
and CXCR4 were classified as R5X4.  
 
4.3.6 Evaluation of CCR3 usage by HIV-1 Envs 
For the pseudovirus entry assays, five-fold serial dilutions of each pseudovirus were prepared 
using DMEM. One hundred microlitre of each dilution was incubated with 1 X 104 U87-CD4 
cells expressing CCR3 in a 96-well plate, in duplicate. The cells were provided DMEM 
supplemented with 1 µg/mL of puromycin (Sigma-Aldrich, St. Louis, USA) and 300 µg/mL of 
G418 (Sigma-Aldrich), then infections were allowed to proceed for 6-12 hours at 37 °C and 5% 
CO2. The medium was changed thereafter and incubation was continued for another 60 hours. 
Then, the medium was discarded, the cells were washed with phosphate-buffered saline and lysed 
with the Luciferase Cell Culture Lysis Reagent (Promega, Madison, WI). The entry of 
pseudoviruses was evaluated by assaying luciferase activity in cell lysates using the Luciferase 
Assay System (Promega). Luminescence was quantified using the Modulus Microplate reader 
(Turner Biosystems, Sunnyvale, CA). A pseudovirus which produced luminescence readings that 
were equal to or greater than 10-fold that of the culture medium without pseudovirus (control) 
was considered as able to infect the cells expressing CCR3. For comparison and assay quality 
control, pseudoviruses pseudotyped with CCR3-using HIV-1 subtype B Envs (HXB2, JR-CSF, 
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NL4.3 YU2 and 89.6) were assayed in parallel. Envs which mediated entry using CCR3 were 
classified as R3.  
 
4.4 Results  
The study participants with CM included in this sub-study were part of a larger cohort study 
described previously. The clinical characteristics of the participants in this sub-study are shown 
in   
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Table 4-1 (28). Here, we report the usage of the CCR3 coreceptor by HIV-1C Envs in eight 
randomly selected participants with matched plasma and CSF, and an additional two and four 
participants with unmatched plasma and CSF samples, respectively. Thus, our analyses were 
based on total of 10 plasma and 12 CSF samples across 14 participants. 
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Table 4-1: The clinical characteristics and samples analyzed of study participants with CM. 
IDa Age Sexb CD4c Pl VLd CSF VLe CSF WBCf Sampleg 
CM019 45 M 7 5.15 4.33 28 Pl and CSF 
CM021 30 F 134 4.34 4.34 40 CSF only 
CM029 33 F 121 5.22 5.99 424 CSF only 
CM032 34 F 5 4.94 2.52 0 Pl and CSF 
CM050 23 F 16 4.92 4.80 6 CSF only 
CM052 24 F 172 4.62 4.83 36 Pl and CSF 
CM054 23 M 7 5.20 4.20 14 Pl only 
CM070 25 M 11 5.04 4.00 18 Pl only 
CM089 27 M 114 5.67 5.85 154 Pl and CSF 
CM094 29 F 35 5.15 4.03 84 CSF only 
CM098 40 M 14 4.76 5.27 66 Pl and CSF 
CM108 27 M 20 5.16 5.02 28 Pl and CSF 
CM117 38 M 1 5.72 4.66 0 Pl and CSF 
CM132 34 M 53 4.58 4.43 38 Pl and CSF 
aThe identification number of the study participant. bThe sex of the study participant, where “M” 
refers to male and “F” refers to female. cThe CD4 count is provided as cells/µL. d,eThe cell-free 
plasma (Pl) and CSF viral load (VL) are presented as log10 HIV RNA copies/mL. fThe CSF white 
blood cell (WBC) count was measured as cells/µL. gThe samples analyzed in this study. 
 
A median of 1.5 (range 1-6) and 1 (range 1-7) plasma and CSF Envs per participant, respectively, 
were included in this study. In total, the alternative coreceptor usage of 46 unique Envs was 
evaluated. Previously, the Envs were identified as subtype C as they clustered with reference 
subtype C sequences (Chapter 2). Overall, of the 46 Envs, 37 (13 plasma; 24 CSF) were R5, three 
(two plasma; one CSF) were R5X4, and six (all from plasma) were X4 based on their ability to 
enter NP2 or U87-CD4 cells expressing CCR5 and CXCR4 (determined in Chapter 3, and 
summarized in Table 4-2). The level of entry mediated into U87-CD4 cells expressing CCR3 by 
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each Env using the CCR3 coreceptor was also determined (Figure 4.1, and summarized in Table 
4-2), while the overall HIV-1C coreceptor usage per compartment of each participant was 
summarized in   
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Table 4-3. Two out of 13 (~15.4%) plasma-derived R5 viruses used CCR3, whereas 11 (~84.6%) 
did not. Seven out of 24 (~29.1%) CSF-derived R5 viruses used CCR3, though 17 out of 24 
(~70.8%) did not. Two of the three (~66.6%) R5X4 plasma-derived viruses used CCR3 and one 
(~33.3%) did not, while the only CSF-derived R5X4 viruses in the study used CCR3. Four out of 
six (~66.6%) plasma-derived X4 viruses used CCR3, whereas the other two (~33.3%) did not. 
Overall, four out of 10 (40%) plasma and five out of 12 (41.7%) CSF samples harbored CCR3-
using viruses. Notably, with the exception of participant CM094 who did not have a plasma 
sample available for evaluation, we identified that usage of CCR3 in plasma accompanied by 
usage of CCR3 in the CSF of CM participants Thus, our results suggest that CCR3 usage by HIV-
1C is common in individuals with end-stage HIV disease and CM, and is not restricted to the 
peripheral blood compartment only. 
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Figure 4.1 (A)  
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Figure 4.1 (B)  
 
Figure 4.1 (A-B): The entry of HIV-1 subtype C pseudoviruses into U87-CD4 cells expressing CCR3. 
HIV-1 subtype C pseudoviruses pseudotyped with participant-derived Envs were engineered to produce luciferase upon successful entry of U87-CD4 
cells expressing CCR3 as described in Materials and methods. Pseudoviruses were diluted 1:1, 1:5, 1:25 and 1:125 with supplemented Dulbecco’s 
modified Eagle’s medium (DMEM) in 100 µL volumes and incubated with U87-CD4 cells expressing CCR3, in duplicate. The mean luciferase activity 
72 hours post-infection in cell lysates was measured as relative light units (RLU). The pseudoviruses with a star symbol beside their name possessed a 
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CSF-derived Env, whereas those without a star possessed a plasma-derived Env (listed on the x-
axis). A background sample consisting of culture medium without pseudovirus (control) was 
included in the assay to determine which Envs facilitated entry: pseudoviruses recording RLU 
values which were at least 10-fold greater (black cutoff line) than the control sample were 
classified as CCR3-using. CCR3-using HIV-1B pseudoviruses pseudotyped with Envs of HXB2, 
JR-CSF, YU2 and 89.6 were also included in the assay for comparison. 
 
Table 4-2: The major and alternative coreceptor usage of HIV-1C Envs. 
IDa Compartment Envb 
Major 
tropism 
Alternative 
tropismc 
CM019 
CSF CM019C.B R5X4 R3 
Plasma 
CM019P.3 X4 R3 
CM019P.B.3 R5X4 R3 
CM019P.B.4 X4 R3 
CM019P.B.5 X4 R3 
CM019P.H.1 R5 - 
CM019P.I.2 R5 - 
CM021 CSF CM021C.7.3 R5 - 
CM029 CSF 
CM029C.B.3 R5 - 
CM029C.D.2 R5 - 
CM029C.E.2 R5 - 
CM032 
CSF CM032C.6.4 R5 - 
Plasma CM032P.6.3 R5 - 
CM050 CSF CM050C_SGA14 R5 - 
CM052 
CSF CM052C.1 R5 - 
Plasma 
CM052P.2.1 R5 - 
CM052P.2.2 R5 - 
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IDa Compartment Envb 
Major 
tropism 
Alternative 
tropismc 
CM054 Plasma CM054P.11.6 R5 - 
CM070 Plasma CM070P.1 X4 - 
CM089 
CSF CM089C_SGA16 R5 - 
Plasma CM089P_SGA06 R5 - 
CM094 CSF 
CM094C.14.2 R5 R3 
CM094C.6.2 R5 - 
CM098 
CSF 
CM098C.C.3 R5 - 
CM098C.F.1 R5 - 
CM098C.F.2 R5 R3 
CM098C.G.1 R5 - 
CM098C.G.2 R5 - 
CM098C.H.1 R5 - 
CM098C.J.4 R5 R3 
Plasma 
CM098P.A.1 X4 - 
CM098P.A.2 X4 R3 
CM098P.B.1 R5 R3 
CM098P.G.1 R5 - 
CM108 
CSF 
CM108C.7.8 R5 R3 
CM108C.8.9 R5 - 
CM108C.B.3 R5 R3 
CM108C.D.8 R5 R3 
Plasma 
CM108P.1 R5X4 R3 
CM108P.D.5 R5 - 
144 
 
IDa Compartment Envb 
Major 
tropism 
Alternative 
tropismc 
CM117 
CSF 
CM117C.A R5 R3 
CM117C.I.1 R5 - 
Plasma 
CM117P.I.1 R5 - 
CM117P.O.1 R5 R3 
CM132 
CSF CM132C.1 R5 - 
Plasma CM132P_SGA02 R5 - 
aThe identification number of the participant. bThe name of an individual Env evaluated. cThe 
Envs which were able to use CCR3 were classified as R3 tropic, shown as “R3”, and those unable 
to use CCR3 were labelled with a dash.  
 
  
145 
 
Table 4-3: The overall coreceptor usage of HIV-1C Envs in each compartment of the study 
participants. 
IDa Plasmab CSFc 
CM019 R3R5X4, R3X4, R5 R3R5X4 
CM021 - R5 
CM029 - R5 
CM032 R5 R5 
CM050 - R5 
CM052 R5 R5 
CM054 R5 - 
CM070 X4 - 
CM089 R5 R5 
CM094 - R3R5, R5 
CM098 R3R5, R3X4, R5, X4 R3R5, R5, 
CM108 R3R5X4, R5 R3R5, R5 
CM117 R3R5, R5 R3R5, R5 
CM132 R5 R5 
aThe identification number of the study participants. b,cThe coreceptor usage phenotypes of Envs 
observed in the plasma and/or CSF samples of the study participants. Dashes indicate where an 
Env was not available for testing from that compartment. Forty percent of plasma and ~41.7% of 
CSF samples harbored CCR3-using viruses. 
 
4.5 Discussion 
Although usage of alternative coreceptors by HIV-1C has been shown in other studies, those 
studies focused largely on viruses circulating in plasma (21-23, 25, 26), whereas our study 
characterized alternative coreceptor of viruses circulating in CSF as well. Limited information 
regarding the alternative coreceptor usage of HIV-1 in the CNS indicates that HIV-1C prefers to 
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use CXCR6 in CSF but not matched plasma (24). We showed that matched plasma and CSF of 
participants with CM harbour HIV-1C variants which use CCR3 for entry, though it was not clear 
from which compartment CCR3 usage arose. Also, due to the limited number of Envs evaluated, 
we were unable to determine whether R5 viruses had a propensity to use CCR3 more than R5X4 
or X4 viruses.  
 
The CCR3 and CCR5 receptors have been shown to support HIV-1 infection of microglia from 
the CNS compartment (16-18). It has also been shown that CCR3 and CCR5 co-localize with 
CD4 at in the plasma membrane of target cells, and that targeting either receptor inhibits HIV-1 
infection (34). In our study we observed a variety of CCR3-using HIV-1C viruses (R3R5, 
R3R5X4 and R3X4) in individuals with CM. This was in contrast with a previous study of HIV-
1C in individuals with active tuberculosis, where all the virus there used CCR5 only (10). We did 
not, however, measure whether or not viruses in this study preferred CCR3 over CCR5 or 
CXCR4. We also did not evaluate whether CCR3-using viruses in the CNS compartment are 
capable of entering microglia or monocyte-derived macrophages. Nevertheless, the observation 
of HIV-1C viruses with expanded coreceptor tropism in the CNS compartment warrants further 
investigations into the pathogenesis of this subtype in that compartment. 
Future studies may include tissue tropism tests to evaluate whether or not HIV-1C Envs with 
expanded coreceptor tropism have the ability to replicate in the CNS compartment. It is also of 
interest to evaluate whether certain AIDS defining illnesses enrich for HIV-1C with alternative 
coreceptor usage, to identify which other alternative coreceptors are used preferentially in the 
CNS, and to identify determinants of alternative coreceptor usage. Given that HIV-1C is the most 
prevalent world-wide, understanding the pathogenesis of this subtype further is of great important.  
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Chapter 5: Discussion 
5.1 Relatedness of HIV-1C env genes in the plasma and CSF 
In this study, we sought to reveal whether Cryptococcus neoformans-HIV co-infection was 
associated with viral genetic intermixing between peripheral blood and the CNS of study 
participants presenting with CM. We hypothesized that Cryptococcus neoformans (or antigens 
thereof) in the CNS may alter the local immunological milieu and lead to the recruitment of HIV-
1 variants into the CNS causing genetic mixing of variants between compartments. We observed 
viral genetic intermixing in all the participants with multiple sequences collected from plasma 
and CSF, thus the results supported our hypothesis.  
All but two participants (CM032 and CM117) in our study had pleocytosis (a marker of CNS 
inflammation), and we suspected that this was a contributing cause of viral genetic intermixing 
between compartments observed in our participants. Pleocytosis was strongly associated with the 
intermixing of viral variants between the blood and CNS compartments previously (254). 
Additionally, another study showed that pleocytosis may alter the dynamics of viral populations 
between the blood and CNS (231). It is, therefore, probable that HIV-1 infected white blood cells 
were trafficked to the CNS compartment, allowing the virus access to the CNS and causing viral 
genetic intermixing as shown by Sturdevant et al (2015) (231). We did not, however, evaluate the 
causes of pleocytosis and whether it occurred transiently or not, therefore pleocytosis in 
participants CM032 and CM117 may have resolved recently and hence genetic mixing was still 
observed between compartments. An alternative explanation may be that the integrity of the 
blood-brain barrier may have been compromised due to HIV-1 or Cryptococcus neoformans 
infection, allowing fluid cell-free traffic of virus across compartments. Overall, we established 
that Cryptococcus neoformans-HIV co-infection is associated with HIV-1C genetic intermixing 
between the peripheral blood and CNS compartments.  
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A previous study showed that SGA, compared to bulk PCR, minimizes the frequency of taq-
induced recombination, nucleotide misincorporation, template switching and template resampling 
(255). Here, we employed SGA as well as bulk PCR as a method of amplification. A possible 
limitation of our methods of amplification was the ability to detect minor variants, which are 
better captured with deep sequencing approaches. Additionally, the low number of sequences we 
collected for the compartments of some participants may have reduced our capacity to detect 
compartmentalized sub-populations of viruses.  
We did not have a control group of participants without CM or with other co-infections, because 
our studies were foremost designed to focus on individuals with CM, so future studies will be 
extended to include adequate control groups to clarify the impact of CM on the viral population 
dynamics between compartments.  
Based on genetic studies of HIV-1 env genes of viruses derived from matched blood and CSF, it 
was shown that the virus may enter the CNS early in primary infection (227, 231). Initial genetic 
comparisons of plasma and CSF-derived HIV-1 were for the understanding of HIV-1 
neurotropism and neurological impairment caused by the virus. They revealed that variants unique 
to the CNS were probably selected for by target cells and immune pressures in the CNS (235). 
Following that, studies revealed that CNS compartmentalized variants were implicated as a cause 
of HAD (224, 226). Employing SGA and sequencing and phylogenetic analyses, a series of 
studies showed that the viral populations in blood may be distinct from those of the CNS (viral 
genetic compartmentalization). Phylogenetically, this meant that there were sub-populations of 
viruses which are represented by CSF-derived viruses only while other populations represented 
plasma-derived viruses only. Alternatively, the compartmentalization may be incomplete or 
partial, where there were sub-populations of viruses which were represented by intermixing 
plasma and CSF-derived variants while other populations represented plasma or CSF-derived 
variants only. In the absence of compartmentalization, there were no sub-populations specific for 
plasma or CSF-derived variants and variants from both compartments were homogenously 
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interspersed or equilibrated (194, 228, 231). These studies were different to ours, however, as 
they were designed for the understanding of HAD in adults, neurological deterioration in infants, 
or the timing of HIV-1 entering the CNS.  
 
5.2 Predicted coreceptor usage of HIV-1C Envs 
A consistent estimate of the prevalence of CXCR4-using HIV-1C is not available. Some studies 
have reported an absence or rare usage of CXCR4 by HIV-1C isolates (72, 169-171, 252, 253), 
while other studies suggest that between 15% and 30% of individuals with end-stage disease 
harbor these isolates (116, 172, 173). Using CPAs, we evaluated the predicted coreceptor usage 
of HIV-1C variants circulating in blood and the CNS of participants with end-stage disease and 
presenting with CM. We observed that predicted R5 variants were present in plasma as well as 
CSF samples; 92.9% and 84.6% of plasma and CSF samples, respectively, harbored predicted R5 
variants. Variants predicted to use CXCR4 were not uncommon in plasma and CSF samples; 50% 
and 30.8% of plasma and CSF samples, respectively, harbored predicted CXCR4-using variants. 
Overall, we identified that the prevalence of predicted CXCR4 usage was high, as approximately 
44% of participants harbored at least one CXCR4-using variant in plasma and/or CSF. Thus, our 
results suggest that approximately 44% of individuals presenting with CM would be ineligible for 
therapy including maraviroc. 
We employed three CPAs (Geno2pheno, WebPSSM, and PhenoSeq) to predict coreceptor usage 
for all variants sequenced in this study (256-258). The three CPAs individually have high 
sensitivity and specificity for predicting coreceptor usage, but may generate conflicting 
predictions between them as we and other have seen (75, 259). Thus, we determined predicted 
coreceptor usage based on the concordance of all three or two of three CPAs in order to maximize 
the accuracy of our determinations. The limitation of using CPAs for coreceptor usage predictions 
is that they may overestimate the prevalence of CXCR4-using variants, as previously described 
(260-264). If the CPAs used overestimated the prevalence of CXCR-using variants, this would 
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mean that some participants would be incorrectly precluded from regimens including maraviroc, 
a CCR5 antagonist. 
Our results, however, confirm those of previous studies showing that the prevalence of CXCR4-
using HIV-1C is high in participants with end-stage disease. Our estimated prevalence of CXCR4 
usage was, unexpectedly, much higher that previously reported, where HIV-1C CXCR4 usage 
was reported in 15% and 30% of participants, according to in vitro phenotypic assays (116, 172, 
173). Our estimate suggests that HIV-1C is able to use CXCR4 frequently in end-stage HIV 
disease. Maraviroc shows good antiviral activity against R5, but is ineffective against CXCR4-
using strains (99). Additional evidence shows that CXCR4-using viruses may emerge from pre-
existing reservoirs under maraviroc treatment (265), and that there is no clinical benefit observed 
with the administration of maraviroc to patients with non-R5 virus (266). Given that HIV-1C in 
patients with CM may use CXCR4, we therefore recommend that viral tropism be screened before 
maraviroc is administered.  
 
Notably, none of the individuals with active tuberculosis in a study by others had isolates which 
used CXCR4 or alternative coreceptors (72). Although that study had a small sample size of 10 
participants, it suggested that active tuberculosis selects for R5 HIV-1C variants. Therefore, it is 
of interest to establish whether or not certain co-infections select for a higher prevalence of 
CXCR4 usage than others, and why. Also, as the presence of CXCR4-using HIV-1C sub-
populations in the CNS has been reported rarely (160), it is also of interest to employ deep 
sequencing methods to identify whether they persist as a minority population or not, and whether 
they are X4 or R5X4 tropic.  
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5.3 Genotypic concordance of HIV-1 coreceptor usage between plasma and CSF 
samples predominates 
The major coreceptor usage of HIV-1 of viral populations in the blood and CNS compartments 
has been compared previously to identify whether or not the pathogenesis of HIV-1 in the CNS 
was different than in the blood compartment, and to ascertain whether coreceptor antagonists like 
maraviroc would be effective in both compartments (223, 249, 250, 267). In this study, we 
evaluated whether participants with end-stage disease and presentation of CM have concordance 
or discordance of HIV-1C predicted coreceptor usage between plasma and CSF samples. We 
identified that 63.6% of participants displayed concordant coreceptor usage, 18.2% displayed 
discordance, and a further 18.2% were indeterminate. This result indicated that coreceptor usage 
in plasma and CSF is not different generally, though discordance is not uncommon, in individuals 
with CM. 
Our results confirm those of previous studies where concordance of coreceptor usage was 
recorded in 54.5% to 89.1% of participants. However, the previous studies evaluated coreceptor 
usage in PBMCs/plasma and CSF samples employing in vitro phenotypic assays (223, 249, 267), 
or CPAs (250). Due to the low number of sequences collected for some participants, we may have 
underestimated the frequency of concordant coreceptor usage between samples.  
 
5.4 In vitro usage of CCR5 and/or CXCR4 by HIV-1C 
Previously, with the aid of CPAs, we identified that HIV-1C in plasma and CSF of participants 
presenting with CM was predicted to use CCR5 and/or CXCR4 for entry. CPAs, however, are 
unable to guarantee biological functionality of Envs, have the potential to overestimate the 
frequency of CXCR4 usage, and have difficulty differentiating between R5X4 and X4 Envs (260, 
262, 264). Thus, we employed in vitro phenotypic assays to confirm the biological functionality 
and coreceptor usage of HIV-1C Envs circulating in the plasma and CSF of participants 
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presenting with CM. Combining the results of the in vitro assays with sequencing information, 
we then evaluated the determinants of HIV-1C CCR5 and CXCR4 usage to see whether they were 
consistent with those identified in previous studies.  
In total, we evaluated the ability of 66 HIV-1C Envs to use CCR5 and/or CXCR4 expressed on 
NP2/U87-CD4 cells. Only 61 Envs were able to use CCR5 and/or CXCR4, while five were not 
able to use the coreceptors. In the 10 plasma samples evaluated, R5, R5X4 and X4 viruses were 
identified in 90%, 20% and 30% of samples, respectively. In the 12 CSF samples evaluated, R5, 
R5X4 and X4 viruses were identified in 91.7%, 8.3% and 0% of samples, respectively. These 
finding suggested that R5, R5X4 and X4 viruses may persist in the blood, but that only R5 and 
R5X4 persist in the CNS. While multiple studies have shown previously using in vitro assays that 
HIV-1C in the blood (from PBMCs or plasma) is capable of using CCR5 and/or CXCR4 (72, 76, 
77, 116, 147, 160, 171, 173, 268), few studies have evaluated the major coreceptor usage of HIV-
1C in the in CSF samples. In CSF samples, R5 viruses predominate while R5X4 viruses are rare 
and X4 viruses have not been recorded (160, 228). Therefore, our results are consistent with those 
of previous studies. Our results were potentially limited by our conservative cut-offs for 
pseudovirus entry in cells lines; only pseudoviruses registering luciferase activity values equal to 
or greater than 10-fold that of controls were qualified as having used CCR5 or CXCR4. Thus, 
Envs which used CCR5 or CXCR4 albeit inefficiently may have been recorded as unable to use 
the coreceptors. 
 
5.5 The performance of CPAs  
We evaluated the accuracy of Geno2pheno, PhenoSeq and WebPSSM for HIV-1C Envs 
individually and collectively. For 45 out of 61 (~73.8%) Envs evaluated in in vitro coreceptor 
usage assays, Geno2pheno, PhenoSeq and WebPSSM provided the same prediction of HIV-1C 
major coreceptor usage. Individually, Geno2pheno was the most accurate of the CPAs when it 
came to predicting R5 viruses, followed by WebPSSM and then PhenoSeq. When it came to 
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predicting CXCR4 usage, all three CPAs were 100% accurate. When a consensus prediction was 
generated, based on the agreement of at least two of three CPAs, this was less accurate for 
predicting R5 viruses compared to using Geno2pheno alone, but was 100% accurate for predicting 
CXCR4 usage. Thus, this suggests that predictions of major coreceptor usage based on a 
consensus of CPAs may not offer more accuracy than using one highly accurate CPA, and that 
Geno2pheno should be favored over the other CPAs. We also noted that six participants were 
predicted to harbor CXCR4-using viruses based on a consensus of CPAs, however, only four of 
those six participants had CXCR4-using viruses based on in vitro assays. This highlights that 
CPAs may overestimate the prevalence of CXCR4 usage, thus some individuals may be precluded 
from using maraviroc incorrectly.  
The three CPAs employed in this study have been shown to be highly accurate, generating 
predictions with high percentage sensitivity and specificity (62, 75, 269). PhenoSeq, originally 
named CoRSeqv3-C, was shown to have superior accuracy than Geno2pheno and WebPSSM, but 
was the least accurate for R5 predictions in our study. Additionally, PhenoSeq was reported to be 
more accurate for predicting CXCR4 usage than Geno2pheno and WebPSSM, however, the three 
CPAs were equally accurate in our study (75). Even though Geno2pheno was designed based on 
HIV-1B sequences (257), it was observed to be the most accurate for predictions of R5 viruses, 
confirming that it performs well for HIV-1C predictions (73, 259). Given that two participants 
were incorrectly predicted to harbor CXCR4-using viruses, it shows that CPAs may overestimate 
the frequency or prevalence of CXCR4, supporting the findings of others (260, 262-264). 
Nevertheless, we were able to show that CPAs are highly accurate generally and may potentially 
replace the employment of in vitro phenotypic assays in resources-limited settings where the latter 
may not be feasible. 
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5.6 Phenotypic discordance of HIV-1 major coreceptor usage between plasma and 
CSF 
Using CPAs, we predicted that the plasma and CSF harbored concordant HIV-1C coreceptor 
usage phenotypes in participant CM098, but discordant phenotypes in participant CM108 (chapter 
2). Employing in vitro phenotypic assays (Chapter 3) were able to show that the coreceptor usage 
phenotypes of HIV-1C in the plasma and CSF of both participant CM098 and CM108 are in fact 
discordant. Participant CM098 possessed R5 and X4 Envs in plasma but R5 Envs only in CSF, 
whereas participant CM108 possessed R5 and R5X4 Envs in plasma but R5 Envs only in CSF. 
This result suggested that functional discordance of Envs may arise between compartments, and 
that these participants are unlikely to benefit from maraviroc treatment as it targets CCR5-tropic 
viruses only and is ineffective against CXCR4-using viruses as previously described (99, 265).   
Participants CM098 and CM108 had a CSF white blood cell (WBC) count of 66 and 28 cells/µL, 
respectively, probably caused by inflammation in the CNS. Even though these participants had 
pleocytosis (a CSF WBC more than 5 cells/µL), different entry phenotypes of HIV-1 between the 
peripheral blood and the CNS were observed. It is unclear whether this was the case because the 
CXCR4-using variants established themselves in the blood recently and were not in sufficient 
concentrations to leak into the CSF. Because we did not sample viruses longitudinally, we were 
unable to explain why the differences of viral phenotypes between compartments were observed. 
Pleocytosis has been shown to cause viral intermixing between peripheral blood and the CNS 
(254), therefore it is possible that CXCR4-using variants may be trafficked to the CNS via 
infected cells where they may establish themselves alongside R5 viruses. Although HIV-1B 
isolates from the CNS have been shown to enter macrophages using CXCR4 (186, 192), CNS 
derived HIV-1C has not been shown to enter macrophages or microglia. We also suspect that 
discordance may be due to the target cells available for HIV-1C in the CNS, which may 
preferentially select for variants which use CCR5 alone or in combination with CXCR4. Others 
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have reported that microglia, major targets for HIV-1 in the CNS, are preferentially infected via 
the CCR5 coreceptor (152-154, 156).  
An early study comparing coreceptor usage phenotypes of HIV-1 in blood (using PBMCs) and 
the CNS (using CSF) revealed that phenotypic discordance arose when SI variants were observed 
in the PMBCs while NSI variants were in CSF (223). A separate study then revealed that 
discordance could arise in one of two ways; when plasma harbored R5 and X4 variants while CSF 
had R5 variants only, or when plasma harbored R5 variants while CSF had R5 and X4 variants 
(267). Discordance was also observed when different coreceptors were used or when usage of 
wild-type CCR5 was different between plasma and CSF. Our studies support those of others 
showing that discordant coreceptor usage of HIV-1 may arise between plasma and CSF, and that 
CXCR4-using viruses are observed in the CSF only when they are also present in the plasma of 
individuals (249). More studies are required to evaluate whether CXCR4-using HIV-1C in the 
CNS is capable of using CXCR4 for entry into macrophages or microglia, as this has implications 
for the pathogenesis of HIV in the CNS and the use of regimens including coreceptors antagonists.  
 
5.7 Determinants of CCR5 and CXCR4 usage 
Multiple studies have shown that R5 and CXCR4-using HIV-1C have different properties of the 
V3 loop. V3 loops of CXCR4-using HIV-1C, compared to R5 HIV-1C, have higher net charge 
and length, but also greater amino acid variability, substitutions of the GPGQ crown motif and a 
reduced number of PNGS (71, 74-76, 116, 171, 270). Combining the results of the in vitro 
phenotypic assays and sequencing information in our study, we were able to identify determinants 
of CCR5 and CXCR4 usage for HIV-1C viruses. CXCR4-using viruses in our phenotypic studies 
were confirmed to have at least two of the following V3 properties: a net charge equal to or greater 
than +5, 37 amino acid acids length, one or two charged residues in the crown motif, and an 
absence of PNGS. In contrast, the V3 sequences of R5 viruses were 35 amino acids in length, had 
a net charge less than +5 and a GPGQ crown motif generally.  
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Most of the R5 viruses in this study had a Env V3 crown motif consisting of a GPGQ sequence, 
except for three viruses, predicted to use CXCR4, from participant CM050 and one from CM108 
(Env CM108P.D.5 had a GPGH, and the Envs from CM050 had a GPGK motif). Given that the 
R5 viruses from participant CM108 and CM050 predicted to be CXCR4-using only had one 
known determinant of CXCR4 usage (an alteration of the GPGQ motif), it is probable that this 
property alone was not sufficient to confer usage of CXCR4. This highlights that HIV-1C may 
require at least two unique properties in the V3 to confer usage of CXCR4. Our results were 
limited in that we did not perform site-directed mutagenesis studies to confirm that the 
determinants we observed modify usage of major coreceptors.  
 
5.8 Alternative coreceptor usage of HIV-1C Envs 
We evaluated whether or not HIV-1C viruses circulating in plasma and CSF were capable of 
using an alternative coreceptor, specifically CCR3, for entry. For our in vitro assay, we measured 
the ability of HIV-1C Envs to mediate entry into U87-CD4 cells expressing CCR3. Our results 
showed that R5, R5X4 and X4 viruses may use CCR3, that usage of CCR3 was concordant 
between plasma and CSF samples, and that approximately 35.7% of participants harbored CCR3-
using viruses in plasma and/or CSF.  
Multiple previous studies focusing on HIV-1C derived from the blood have shown that HIV-1C 
virus is capable of using CCR3 (146, 147, 158, 159). In one study including five participants 
harboring HIV-1C, multiple isolates in the CSF were observed to use CXCR6, while few were 
able to use GPR1 or CCR3. Furthermore, the use of alternative coreceptors was also limited to 
the CSF and not observed in plasma suggesting functional compartmentalization of virus (160). 
Our results confirm those of previous studies indicating that HIV-1C in peripheral blood during 
end-stage disease uses CCR3, however, we additionally observed that usage of CCR3 was 
frequent in CSF samples. A possible limitation of this analysis was the selection of a conservative 
cut-off for CCR3 usage in our in vitro phenotypic assay, which may have led to under-reporting 
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of CCR3 usage. The frequent detection of R3R5 and R5 viruses in CSF samples in our study 
suggest that CCR5 and CCR3 are important for HIV-1C entry in the CNS. HIV-1 has been shown 
to enter microglia using CCR5 and CCR3 (152, 154-156), suggesting that viruses in our study 
may have the ability to enter this cell type.   
This analysis was limited by the fact that we did not evaluate whether or not the CCR3-using 
Envs were capable of mediating infection of monocyte-derived macrophages or microglia using 
CCR3. 
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Chapter 6: Conclusions 
In summary, our studies elucidated the genotypic and phenotypic properties of HIV-1C in 
antiretroviral therapy naïve individuals with end-stage HIV disease and CM. We revealed the 
phylogenetic relatedness of HIV-1C env gene sequences from the peripheral blood and CNS 
compartments, and estimated the prevalence of CXCR4 usage in antiretroviral naïve individuals 
with CM using CPAs.  Additionally, we determined the in vitro usage of major coreceptors (CCR5 
and CXCR4) and an alternative coreceptor (CCR3) by HIV-1C in peripheral blood and CNS 
compartments. This allowed us to reveal determinants of CCR5 and CXCR4 usage by HIV-1C 
viruses when combining our in vitro phenotypic assay results with sequencing information. We 
also were able to clarify the accuracy of publicly available CPAs, individually and in combination. 
Thus, our studies have improved our understanding of HIV-1C gene flow between the peripheral 
blood and CNS compartments, revealed the coreceptor usage phenotype of viral variants in 
individuals with end-stage HIV disease with CM, clarified the eligibility of individuals with CM 
for using maraviroc and assisted with the refinement of CPAs.  
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Chapter 7: Recommendations 
In this study, we demonstrated that individuals with end-stage HIV-1 disease presenting with CM 
have trafficking of virus between the blood and CNS compartments. However, the compartmental 
origins of the viruses we sequenced were unclear; they may have been produced in the blood and 
trafficked to the CNS or vice versa. Future studies may investigate the identity of the cells which 
produced the viruses we observed in plasma and the CSF. Additionally, deep sequencing tools 
may be employed to enhance the detection of minor variants not observed in the two 
compartments. 
We characterized the predicted and in vitro coreceptor usage of HIV-1C in our study, but did not 
measure the efficiency of coreceptor usage or the tissue-tropism of viruses. As the efficiency of 
coreceptor usage or targeting of tissues may be different between compartments, other types of 
functional compartmentalization may be investigated in future. Furthermore, it is of interest to 
investigate whether individuals presenting with CM have macrophage-tropic variants in the blood 
and/or CNS, and to identify where they originate if so.  
Our study showed that HIV-1C may have expanded coreceptor usage, but we only tested the 
ability of viruses to use one alternative coreceptor, CCR3. Future studies may explore the usage 
of other alternative coreceptors in the CNS of individuals with end-stage HIV-1 disease, in the 
absence and presence of CM, and whether or not microglia are infected by HIV-1C. This may 
also allow us to identify the determinants of alternative coreceptor usage and the pathogenesis of 
HIV-1C in the CNS. Additionally, the implications of expanded coreceptor usage of HIV-1C for 
disease progression require further investigation.  
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